CN103357015A - Local preparation for removing verruca and nail diseases and taking care of nails - Google Patents

Local preparation for removing verruca and nail diseases and taking care of nails Download PDF

Info

Publication number
CN103357015A
CN103357015A CN2013102038263A CN201310203826A CN103357015A CN 103357015 A CN103357015 A CN 103357015A CN 2013102038263 A CN2013102038263 A CN 2013102038263A CN 201310203826 A CN201310203826 A CN 201310203826A CN 103357015 A CN103357015 A CN 103357015A
Authority
CN
China
Prior art keywords
acid
α
methyl
yl
β
Prior art date
Application number
CN2013102038263A
Other languages
Chinese (zh)
Inventor
汉斯·梅尔
Original Assignee
瑞士商拜欧伊果公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商拜欧伊果公司 filed Critical 瑞士商拜欧伊果公司
Priority to CN2013102038263A priority Critical patent/CN103357015A/en
Priority to CN200510105663.02005.09.29 priority
Publication of CN103357015A publication Critical patent/CN103357015A/en

Links

Abstract

The invention relates to an anhydrous product for a local part, and the product is used for removing verruca and nail diseases and taking care of nails. The product comprises one or more active components, one or more of lactic acid, malic acid, tartaric acid, nitric acid, and C1-C4-alkyl ester of hendecanoic acid or undecylenic acid, serving as a carrier, and biocompatible auxiliary agents which are optional according to requirements. The invention also relates to a method for preparing the product and an application thereof.

Description

疣、指甲疾病、及指甲保养用之局部配方 Topical formulations warts, nail disease, nail care and use of

[0001] 本申请是申请日为2005年9月29日、申请人为瑞士商拜欧伊果公司、发明名称为“疣、指甲疾病、及指甲保养用之局部配方”的中国专利申请200510105663.0的分案申请。 [0001] This application is filed September 29, 2005, if the applicant is a Swiss business Baiou Yi Company, entitled "warts, nail diseases, and the use of topical formulations Nail Care" in Chinese patent application 200510105663.0 of points case application.

技术领域 FIELD

[0002] 本发明是有关一种无水的局部用产品,用于治疗疣、指甲疾病与指甲保养,其包含一种或多种活性成份、作为载剂的一种或多种乳酸、苹果酸、酒石酸、柠檬酸、十一烷酸或十一碳烯酸的C1-C4-烷基酯,与可视需要选用的生理上可兼容的辅剂。 [0002] The present invention relates to an anhydrous topical products for the treatment of warts, nail care and nail diseases, which comprises one or more active ingredients, one or more of lactic acid as carrier agents, malic acid , tartaric acid, citric acid, undecanoic acid, undecylenic acid or C1-C4- alkyl ester, optionally with optional physiologically compatible adjuvants.

[0003] 本发明亦有关一种制备此等调配物的方法及其应用。 [0003] The present invention also relates to a process for preparing such formulations and their application.

背景技术 Background technique

[0004] 抚(Verruca)是经由病毒,特别是乳头状瘤多瘤空泡化病毒(Papovaviruses)所引起,大多为在称为角蛋白的凝集角状皮肤下皮肤乳头状组织的良性过度增生物质,不容易渗入。 [0004] Fu (verruca) via viruses, in particular papilloma virus polyoma vacuolization (Papovaviruses) caused, mostly papillary benign hyperproliferative skin tissue under the skin angular aggregated substance called keratin not easy to penetrate. 至少有50种不同皮肤过度增生物质被归类为疣,且其是由超过100种疣病毒所引起,亦即乳头状瘤病毒。 There are at least 50 different skin hyperplasia substance is classified as warts, and it is composed of more than 100 kinds of viruses that cause warts, namely papilloma virus. 其中特别分成线状疣,呈长条形过度增生物质出现在脸部、颈部或眼脸。 Into a particular line warts, hyperproliferative elongated strip material appeared on the face, neck, face or eyes. 平面状疣出现在脸部、手背、颈部或胸部。 Flat warts on the face, back, neck or chest. 此等疣可能因抓痒或刮胡子而扩散。 These warts may be due to scratching or shaving and spread. 此外尚有所谓棒状疣,其外形极类似花菜,会出现在头部或颈部,或有一种出现在手指与手部的甲周疣,亦经常出现在指甲周围。 Additionally, there are so-called coryneform warts, cauliflower closely resembles its shape, will appear in the head or neck, or appear to have a finger and periungual warts of the hand, it is also often present around the nail. 此外,更困扰且麻烦的疣出现在脚底,称为刺状疣,极难治疗。 In addition, more troubled and troublesome warts appear in the soles of the feet, known as spiny warts, extremely difficult to treat. 疣、指甲疾病与指甲保养的局部治疗没有副作用且治疗成本低。 Topical treatment of warts, nail diseases and nail maintenance therapy without side effects and low cost. 排除疣及局部用调配物于指甲治疗及指甲保养上的应用的主要问题在于如何使足量活性成分与辅剂通过疣的角质层或指甲,渗入需治疗的深部组织中,以排除角质层下的病原菌,例如:病毒与霉菌感染。 Negative warts and topical formulations in that the main problem in the application on the nails and nail care and treatment of how to make a sufficient amount of active ingredient and adjuvants through the stratum corneum of the wart or nails, penetrate deep tissue to be treated so as to exclude the stratum corneum pathogens, such as: viral and fungal infections. 采用一般方法即可治疗现有的病原菌,且可藉由直接局部治疗而消除其症状。 Prior to treatment using the general method of pathogens, and can be eliminated by direct local treatment of their symptoms. 但大多数情况下,在停止治疗后,其症状可能复发。 But in most cases, after stopping the treatment, the symptoms may recur. 已知可采用某些自然方法治疗疣,但无法真正保证成功,因为皮肤及角质层的渗透仍是问题。 Known methods can be some natural treatment of warts, but can not really guarantee success, because the penetration of the skin and cuticle remains a problem.

[0005] 已有人提出直接局部施用活性成分来改善治疗结果的方法,其中活性成分是与所谓的载剂一起使用,亦即此物质除了提高活性成分的溶解度外,尚对通过角质层及指甲具有良好通透性,且有能力运送活性成分通过指甲组织。 [0005] A method has been proposed to direct topical application of the active ingredient to improve the treatment outcome, wherein the active ingredient is used in conjunction with a so-called carrier, i.e., increase the solubility of the substance in addition to the active ingredient, but still on the nail through the stratum corneum and having good permeability, and the ability to transport active ingredients through the nail tissue. 例如:EP-AO 503 988中所说明治疗甲霉菌病的医药中除了抗霉菌活性成分与水性介质(其至少部份溶解抗霉菌剂)外,尚包含至少一种可促进抗霉菌剂渗透指甲的亲水性物质。 For example: EP-AO 503 988 described treatment of nail mycosis pharmaceutical antimycotic active ingredients, in addition to the aqueous medium (which is at least partially dissolved antimycotic agent), but still comprising at least one antimycotic agents promoting penetration of the nail hydrophilic substances. 除了许多种化合物外,亦述及以乳酸乙酯作为促进渗透的物质。 In addition many compounds, also mentioned in ethyl lactate as the penetration promoting substance. 该说明于EP-AO 503 988的调配物由于仅可部份溶解活性成分,因此仅适用于限量的活性成分。 The formulations described in EP-AO 503 988 was only partially due to the dissolution of the active ingredient, and therefore applies only to a limited amount of the active ingredient. 此外,就调配物中水含量的观点而言,当使用可水解的化合物(如:乳酸乙酯)作为促进渗透物质时,无法制备稳定的调配物,因为此等化合物会在储存期间因水解而分解。 Furthermore, the water content formulation was viewpoint, when using hydrolysable compounds (such as: ethyl lactate) as a penetration promoting substance, stable formulations can not be prepared, since such compounds will be hydrolyzed during storage because the break down.

[0006]目前尚无令人满意的产品可用于局部治疗指甲疾病或局部保养指甲,其中所含的载剂应可保证长期传送所需量活性成分通过角质层及指甲,进入指甲床及指甲基部。 [0006] There is no satisfactory product can be used for local treatment of a disease or a nail care and nail topical, the carrier may be contained therein should ensure long-term desired amount of active ingredient transport through the stratum corneum and the nail into the nail bed and nail base .

发明内容[0007] 因此,本发明的目的在于解决与消除疣、局部治疗指甲疾病及局部保养指甲有关的问题,并提供一种可长期使用的医药与美容保养品。 SUMMARY [0007] Accordingly, the present invention is to solve and eliminate warts, topical issues relating to the treatment of nail diseases and nail care locally, and provide medicine and beauty care products A long-term use.

[0008] 因此,本发明的目的在于解决与消除疣、局部治疗指甲疾病及局部保养指甲有关的问题,并提供一种可长期使用的医药与美容保养品。 [0008] Accordingly, an object of the present invention is to solve and eliminate warts, topical treatment of nail diseases and problems associated local nail care, and provides a pharmaceutical and beauty care products A long-term use.

[0009] 根据本发明一种无水的局部用产品,其可治疗疣,治疗指甲疾病及保养指甲,其组成如下: [0009] According to the present invention, an anhydrous topical products that treat warts, nail care and treatment of nail diseases, having the following composition:

[0010] a) 一种或多种活性成份, [0010] a) one or more active ingredients,

[0011] b)作为载剂的一种或多种乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4烷基酯,及 [0011] b) as a carrier of one or more of lactic, malic, tartaric, citric, i ^ i ^ an acid or a carbon acid esters of C1-C4 alkyl, and

[0012] c)可视需要选用的生理上可兼容的辅剂。 [0012] c) optionally physiologically compatible adjuvants selected.

[0013] 在一个实施例中,所述局部用产品其特征在于,其包含乳酸、苹果酸、酒石酸、柠檬酸、十一烷酸或十一碳烯酸的乙酯作为载剂。 [0013] In one embodiment, the topical product characterized in that it comprises lactic acid, malic acid, tartaric acid, citric acid, undecanoic acid or undecylenic acid ethyl ester as carrier.

[0014] 在另一个实施例中,所述局部用产品其特征在于,其中包含乳酸、苹果酸、酒石酸、朽1檬酸、i 烧酸或i 碳烯酸的异丙基酯作为所述载剂。 [0014] In another embodiment, the topical product, wherein containing lactic acid, malic acid, tartaric acid, citric acid rot 1, i i acid, or carbon burning acid isopropyl ester as a carrier agents.

[0015] 在一个实施例中,所述的局部用产品其特征在于,其包含乳酸乙酯作为所述载剂。 [0015] In one embodiment, the topical product characterized in that it comprises ethyl lactate as the carrier.

[0016] 消除疣的特别重要产品为包含金钟柏油的制剂。 [0016] eliminate warts is particularly important for the preparation of products containing Thuja oil.

[0017] 在一个实施例中,所述的局部用产品其特征在于,其包含一种或多种选自下列各物所组成群中的物质作为所述活性成分:合成或天然的抗霉菌剂、抗生素、抗菌剂、皮质类固醇及滋养与合成代谢物质。 [0017] In one embodiment, the topical product characterized in that it comprises one or more selected from the group consisting of the following composition of matter as the active ingredient: synthetic or natural antimycotic , antibiotics, antibacterial agents, corticosteroids and anabolic substances nourishment.

[0018] 在另一个实施例中,所述的局部用产品其特征在于,其包含一种或多种选自下列各物所组成群中的所述抗霉菌活性成份:(±)-顺式_2,6- 二甲基-4- [2-甲基-3-(对-叔戍基-苯基)丙基]吗啉(安莫芬(Amorolfin))、两性霉素(Amphotericin)、6_环己基-1-轻基-4-甲基-2 (IH)-卩比唳酮(环匹罗司(Ciclopirox))、双-苯基-(2-氯苯基)-1-咪唑基甲烷(克霉唑(Clotrimazol))、1_[2_(2,4-二氯苯基)-2-(4-氯苯甲基氧)-乙基]-咪唑(益康唑(Econazol))、2,4-二氟-α,α-双(1Η-1,2,4_三唑-1-基甲基)苯甲基醇(氟康唑(Fluconazol))、5_氟胞卩密丨淀(安确治(Flucytosin))、7_氯-三甲氧基-甲基螺-[苯并呋喃-环己烯]-二酮(灰黄霉素(Griseofulvin))、1-[2,4-二氯-β-(2,6-二氯苯甲基氧)-苯乙基]-咪唑(异康唑(Isoconazol))、(±)-1-仲丁基-4-{4-[4-(4-{[ (2R*,4S*)-2-(2,4- 二氯苯基)-2-(1,2, 4-三唑-1-基甲基)-1,3- 二氧戊环-4-基]甲氧基}苯基)-1-哌 [0018] In another embodiment, the topical product characterized in that it comprises one or more selected from the group of each composition consisting of antimycotic active ingredients: (±) - cis _2,6--dimethyl-4- [2-methyl-3- (p - tert - pentyl - phenyl) propyl] morpholine (An Mofen (Amorolfin)), amphotericin (amphotericin), 6_ light cyclohexyl-1-yl-4-methyl -2 (IH) - one Jie Li ratio (ciclopirox (ciclopirox)), bis - phenyl - (2-chlorophenyl) -1-imidazol methane (clotrimazole (clotrimazol)), 1_ [2_ (2,4- dichlorophenyl) -2- (4-chlorobenzyl-oxy) - ethyl] - imidazole (econazole (Econazol)) , 2,4-difluoro -α, α- bis (1Η-1,2,4_ triazol-1-ylmethyl) benzyl alcohol (fluconazole (Fluconazol)), 5_-fluoro-cell adhesion Jie Shu starch (determined security rule (Flucytosin)), 7_ chloro - trimethoxy - methyl - spiro - [benzofuran - cyclohexenyl] - dione (griseofulvin (griseofulvin)), 1- [2, 4- dichloro -β- (2,6- dichlorobenzyl oxy) - phenethyl] - imidazole (isoconazole (Isoconazol)), (±) -1- sec-butyl-4- {4- [4- (4 - {[(2R *, 4S *) - 2- (2,4- dichlorophenyl) -2- (1,2,4-triazol-1-ylmethyl) -1, 3- dioxolan-4-yl] methoxy} phenyl) -1- 基]苯基}-4,5-二氢-1,2,4-三唑-5-酮(伊曲康唑(Itraconazol) ),(±)顺式-1-乙酰基_4_ {4-([2-(2,4-二氯苯基)-2-(1H-咪唑-1-基甲基)-1,3- 二氧戍环-4-基]甲氧基)苯基}哌嗪(酮康唑(Ketoconazol))、1_[2,4- 二氯-β -(2, 4-二氯苯甲基氧)-苯乙基]-咪唑(咪康唑(Miconazol))、(E)-N-肉桂基-N-甲基-1-萘基甲基胺(萘替芬(Naftifin))、制霉菌素(Nystatin)、(E)-(6,6-二甲基-2-庚烯-4-炔基)-N-甲基-1-萘基甲基胺(特比萘芬(Terbinaf in))、1-[2-{(2-氯-3-噻吩基)甲氧基}-2-(2,4_ 二氯苯基)乙基]-1H-咪唑(噻康唑(Tioconazol))、0-2-萘基-N-甲基-N_(3-甲苯基)_硫代氨基甲酸酯(托萘酯(Tolnaftat))、α-(2,4_ 二氟苯基)-5_氟-β -甲基-α-(1Η_1,2,4-三唑-1-基甲基)-4-嘧啶乙醇(伏立康唑(Voriconazol))。 Yl] phenyl} -4,5-dihydro-1,2,4-triazol-5-one (Itraconazole (Itraconazol)), (±) cis -1-acetyl-4- {_4_ ([2- (2,4-dichlorophenyl) -2- (1H- imidazol-1-ylmethyl) -1,3-dioxo Shu-4-yl] methoxy) phenyl} piperidine piperazine (ketoconazole (Ketoconazol)), 1_ [2,4- dichloro -β - (2, 4- dichlorobenzyl oxy) - phenethyl] - imidazole (miconazole (Miconazol)), ( E) -N- -N- methyl-cinnamyl-1-naphthyl methylamine (naftifine (Naftifin)), nystatin (nystatin), (E) - (6,6- dimethyl-2 - hept-en-4-yn-yl) -N- methyl-1-naphthylmethyl amine (terbinafine (Terbinaf in)), 1- [2 - {(2- chloro-3-thienyl) methyl oxy} -2- (2,4_-dichlorophenyl) ethyl] -1H- imidazole (tioconazole (Tioconazol)), 0-2- naphthyl -N- methyl -N_ (3- methylphenyl) _ thiocarbamate (tolnaftate (Tolnaftat)), α- (2,4_-difluorophenyl) -5_ fluoro -β - methyl -α- (1Η_1,2,4- triazol -1 - ylmethyl) -4-pyrimidinyl ethanol (voriconazole (Voriconazol)). [0019] 在一个实施例中,所述的局部用产品,其特征在于其包含一种或多种选自:茶树精油、熏衣草油、金钟柏油、印楝树提取物和ABC油中的所述抗细菌或所述抗霉菌活性成分。 [0019] In one embodiment, the topical product, characterized in that it comprises one or more selected from: tea tree oil, lavender oil, thuja oil, neem tree oil extract and ABC the said anti-mycotic or antibacterial active ingredient.

[0020] 在一个实施例中,所述的局部用产品,其特征在于其包含一种或多种选自下列各物所组成群中的所述抗生素活性成份:α -氨基-4-羟基苯甲基青霉素(羟氨苄青霉素(Amoxicillin))、D-(-)-α -氨基苯甲基青霉素(氨节青霉素(Ampicillin))、3,3- 二甲基-7-氧代-6-苯基乙酰胺基-4-硫杂-1-氮杂双环-[3.2.0]-庚烷-2-羧酸(苄青霉素)、苄青霉素-苄星、3-氯-7-D(2-苯基甘氨酸氨基)-头孢酸(头孢克洛(Cefaclor))、7β-0)-2-氨基-(4-羟基-苯基)-乙酰基氨基]_3_甲基-头孢酸(头孢羟氨(Cefadroxil))、氨基苯基-乙酰氨基-甲基-头孢酸(头孢氨苄(Cefalexin))、D (-)-对-2- 二氯乙酸氨基-1- (4-硝基苯基)-1, 3-丙二醇(氯霉素(Chloramphenicol)、1-环丙基-6-氣-1,4- 二氧~4~氧代-7-(1-喊嚷基)~3~喧琳竣酸(环丙沙星(Ciprofloxacin))、(Z) - (2R, 5R) -3- (2-羟基亚乙基)~7~ 氧代-4-氧杂-1-氮杂双环[3.2.0]庚烧-2-羧酸(克拉维酸(Clavulanic acid))、7 [0020] In one embodiment, the topical product, characterized in that it comprises one or more selected from the group consisting of each composition of the antibiotic active ingredient: α - amino-4-hydroxyphenyl methyl penicillins (amoxicillin (amoxicillin)), D - (-) - α - amino benzyl penicillin (ampicillin (ampicillin)), 3,3- dimethyl-7-oxo-6-phenyl yl acetamido-4-thia-1-azabicyclo - [3.2.0] - heptane-2-carboxylic acid (benzylpenicillin), benzylpenicillin - benzathine, 3-chloro -7-D (2- phenylglycine amino) - cephem acid (cefaclor (cefaclor)), 7β-0) -2- amino - (4-hydroxy - phenyl) - acetylamino] methyl _3_ - cephem acid (cefadroxil (Cefadroxil)), amino phenyl - acetamido - methyl - cephem acid (cephalexin (cefalexin)), D (-) - of acid-2-amino-1- (4-nitrophenyl) - 1, 1,3-propanediol (chloramphenicol (chloramphenicol), 1- cyclopropyl-6-dioxo-1,4 ~ gas ~ 4-oxo-7- (1-Hanrang yl) ~ 3 ~ noise Lin Jun acid (ciprofloxacin (ciprofloxacin)), (Z) - (2R, 5R) -3- (2- hydroxyethylidene) ~ ~ 7-oxo-4-oxa-1-azabicyclo [3.2. 0] hept-2-carboxylic acid burn (clavulanic acid (clavulanic acid)), 7 _氯-7-脱氧-林可霉素(氯林可霉素(Clindamycin))、6_脱氧-5-轻基四环素(强力霉素(Doxycyclin))、1-乙基-6-氟-1,4- 二氢-4-氧代-7- (1-哌嗪基)-1, 8-萘啶_3_羧酸(依诺沙辛(Enoxacin))、红霉素、3-(2-氯-6-氟苯基)-5_甲基-4-异恶唑基-青霉素(氟氯西林(Flucloxacillin))、卡那霉素(Kanamycin)、林可霉素(Lincomycin)、7-二甲基氛基-6-脱氧-6-去甲基四环素(二甲胺四环素(Minocyc-lin))、6-(2_乙氧基-1-萘酰胺基)_青霉素(萘夫西林(Nafcilin))、1-乙基-1,4-二氢-7-甲基_4_氧代-1,8-萘啶-3-羧酸(萘唳酮酸(Nalidxic acid))、新霉素(Neomycin)、1-乙基_6_ 氟-1, 4_ 二氢~4~ 氧代-7- (1-哌嗪基)-3-喹啉羧酸(诺氟沙星(Norfloxacin))、(±) _9_氟-2,3- 二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de] [1,4]苯并恶嗪_6_羧酸(氧氟沙星(Ofloxacin) )、6_ (5-甲基_3_苯基-4-异恶唑羧酰胺基)青霉烷酸(甲苯异恶唑青霉素(Oxacillin))、6_苯氧基乙 _-Chloro-7-deoxy - lincomycin (clindamycin (Clindamycin)), 6_ light-deoxy-5-yl tetracycline (doxycycline (Doxycyclin)), 1- ethyl-6-fluoro-1 , 4-dihydro-4-oxo-7- (1-piperazinyl) -1, 8-naphthyridine _3_ acid (by Nuosha Xin (Enoxacin)), erythromycin, 3- (2 - chloro-6-fluorophenyl) methyl-4-isoxazolyl -5_ - penicillin (flucloxacillin (flucloxacillin)), kanamycin (kanamycin), lincomycin (lincomycin), 7- atmosphere dimethyl-6-deoxy-6-demethyl-tetracycline (minocycline (Minocyc-lin)), 6- (2_ amido-ethoxy-1-naphthyl) _ penicillin (nafcillin ( Nafcilin)), 1- ethyl-1,4-dihydro-7-methyl _4_ oxo-1,8-naphthyridine-3-carboxylic acid (Li-naphthalene acid (Nalidxic acid)), neomycin Su (Neomycin), ethyl 1- _6_ fluoro-l, 4 ~ 4_ ~ dihydro-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (norfloxacin (norfloxacin)), (±) _9_-fluoro-2,3-dihydro-3-methyl-10- (4-methylpiperazin-1-piperazinyl) -7-oxo -7H- pyrido [1,2,3 de] [1,4] benzoxazine _6_ acid (ofloxacin (ofloxacin)), 6_ (5- methyl-_3_-phenyl-4-isoxazole carboxamide yl) penam acid (toluene-isoxazolyl penicillin (Oxacillin)), 6_ phenoxyacetate 基氨基-青霉烷酸(苯氧基甲基青霉素)与4-二甲基胺基-八氢-五羟基-1,11- 二氧代-6-甲基-萘并萘-2-脲(四环素)。 Group - penicillanate (phenoxymethyl penicillin) with 4-dimethylamino - octahydro - five-1,11-dioxo-6-methyl - urea naphthalene and naphthalene-2 (tetracycline).

·[0021] 在另一个实施例中,所述的局部用产品,其特征在于其包含一种或多种选自下列各物所组成群中的所述抗菌活性成分:烷基苯甲基二甲基氯化铵(苯扎氯氨)、N-苯甲基-N,N-二甲基-2-{2-[对-(1,1,3, 3-四甲基丁基)-苯氧基]-乙氧基}-乙基氢氧化铵(氯化节乙氧铵)、鲸腊基三甲基氢氧化铵(西曲溴铵(Cetrimonium bromid))、 * [0021] In another embodiment, the topical product, said characterized in that it comprises one or more selected from the group consisting of each composition of an antimicrobial active ingredients: alkyl dimethyl chloride (benzalkonium chloride, ammonia), N- benzyl -N, N- dimethyl-2- {2- [p - (1,1,3,3-tetramethylbutyl) - phenoxy] - ethoxy} - ethyl ammonium hydroxide (v benzethonium chloride), cetyl trimethyl ammonium hydroxide (cetrimide (cetrimonium bromid)),

I, I'-六亚甲基-双-[5_(对氯苯基)-双缩胍](洗必泰(Chlorhexidin))、N1, N1-十亚甲基-双_(4_氨基甲基喹哪唳鐵氢氧化物)(克菌定(Dequalinium chlorid))、N-(4_氯苯基)-N' _(3,4-二氯苯基)脲(三氯二苯脲(Triclocarbane))、5_ 氯-2-(2, 4-二氯苯氧基)苯酹(三氯生(Triclosan))。 I, I'- hexamethylene - bis - [5_ (p-chlorophenyl) - biguanide] (Chlorhexidine (Chlorhexidin)), N1, N1- decamethylene - _ bis (carbamoyl 4_ yl quinolin which Li iron hydroxide) (dequalinium (dequalinium chlorid)), N- (4_ chlorophenyl) -N '_ (3,4- dichlorophenyl) urea (triclocarban ( Triclocarbane)), 5_-chloro-2- (2,4-dichlorophenoxy) phenyl sprinkle (triclosan (triclosan)).

[0022] 在一个实施例中,所述的局部用产品,其特征在于其包含一种或多种选自下列各物所组成群中的所述皮质类固醇活性成分:9 α -氯-16 β -甲基氢化波尼松(倍氯米松(Beclomethason))、9-氟-11 β,17,21-三羟基-16 β -甲基-1,4-孕二烯-3,20- 二酮(倍他米松(Betamethason)) >21-氯-9-氟-11 β , 17- 二轻基-16 β -甲基-1, 4-孕二稀-3, 20- 二丽(氣倍米松(Clobetasol))、17, 21- 二轻基-孕-4-稀-3, 11, 20- 二酮(可的松(Cortisone))、11 β,16 α,17 α ,21-四羟基-1,4-孕二烯-3,20- 二酮-16,17-丙酮缩醛(丙缩羟强龙(Desonid))、9_氟-11 β-17,21-三羟基-16 α-甲基孕留-1, 4- 二烯-3,20- 二酮(地塞米松(Dexamethason))、9 α,11 β - 二氯_6α -氟-21-羟基_16α,17α -(异亚丙基二氧)-孕甾-1,4- 二烯-3,20- 二酮(氟氯奈德(Flucloronid))、6 α,9 α - 二氟-16 α, 17 α -异亚丙基二氧-皮质酮(肤轻松(Fluocinolonacetonid) )、6α,9α -二氟-16 α, 17 [0022] In one embodiment, the topical product, characterized in that it comprises one or more selected from a corticosteroid active ingredient group consisting of the following composition: 9 α - chloro -16 β - methyl prednisolone (beclomethasone (Beclomethason)), 9- fluoro -11 β, 17,21- trihydroxy -16 β - methyl-1,4-pregnadiene-3,20-dione (betamethasone (Betamethason))> 21- chloro-9-fluoro--11 β, 17- two light-yl -16 β - methyl-1, 4-diene--3 progesterone, 20-Li (gas fold dipropionate (Clobetasol)), 17, 21- two light-yl - pregn-4 dilute -3, 11, 20-dione (hydrocortisone (cortisone)), 11 β, 16 α, 17 α, 21- tetrahydroxy - 1,4-diene-3,20-dione 16,17-pregnant acetone acetal (prop-hydroxyethyl condensing prednisolone (Desonid)), 9_ fluoro -11 β-17,21- trihydroxy -16 α- methylpregn left-1,4-diene-3,20-dione (dexamethasone (dexamethason)), 9 α, 11 β - dichloro _6α - fluoro-21-hydroxy-_16α, 17α - (iso propylidene-dioxy) - pregna-1,4-diene-3,20-dione (budesonide chlorofluorocarbons (Flucloronid)), 6 α, 9 α - difluoro -16 α, 17 α - isopropylidene propyl dioxo - corticosterone (fluocinolone (Fluocinolonacetonid)), 6α, 9α - difluoro -16 α, 17 α -异亚丙基二氧-皮质酮-乙酸盐(醋酸氟轻松(Fluocinonid))、6 α -氟-11 β,21- 二轻基-6 α,17-异亚丙基二氧-4-孕烯-3,20- 二酮(氟氢缩松(Fludroxycortid))、3_(2_氯乙氧基)_9α -氟-6-甲酰基-11β,21- 二羟基-16α,17α -异亚丙基二氧孕-3,5- 二烯-20-酮(福莫可他(Formocortal)) >21-氯_9 α -氟-11 β -轻基-16 α,17 α -异亚丙基二氧-4-孕烯-3,20-二酮(哈西萘德(Halcinonid) )、17 α-羟基皮质酮(氢化可的松(Hydrocortison))、11 β,17, 21-三轻基-6 α -甲基-1, 4-孕二烯-3,20-二酮(甲基氢化泼尼松(Methylprednisolon))、11 β,17, 21-三轻基-孕-1, 4- 二烯-3, 20- 二酮(强的松龙(Prednisolon))、17 α,21- 二轻基-孕-1, 4- 二烯-3, 11, 20-三酮(泼尼松(Prednison))、9-氟-16 α-羟基氢化泼尼松(丙酮氟羟泼尼松龙(Triamcinolon))、丙酮氟羟泼尼松龙-16 α,17 α -丙酮化物(曲安奈德(Triamcinolonacetonid))。 [alpha] - isopropylidene-dioxo - Corticosterone - acetate (fluocinolone (Fluocinonid)), 6 α - fluoro -11 β, 21- two light-yl -6 α, 17- dioxo-isopropylidene - 4- pregnene-3,20-dione (flurandrenolide (Fludroxycortid)), 3_ (2_ chloroethoxy) _9α - fluoro-6-formyl -11β, 21- dihydroxy -16α, 17α - isopropylidene-dioxo-3,5-dien-20-one progestin (formocortal (formocortal))> 21- chloro _9 α - fluoro -11 β - light-yl -16 α, 17 α - iso propylidene-dioxo-4- pregnene-3,20-dione (naphthalene de hash (Halcinonid)), 17 α- hydroxy corticosterone (hydrocortisone (Hydrocortison)), 11 β, 17, 21- three light-yl -6 α - methyl-1,4-pregnadiene-3,20-dione (methylprednisolone (Methylprednisolon)), 11 β, 17, 21- three light-yl - pregnant -1 , 4-diene -3, 20-dione (prednisolone (Prednisolon)), 17 α, 21- two light-yl - pregnancy-1,4-diene -3, 11, 20- trione (splash prednisone (Prednison)), 9- fluoro -16 α- hydroxy-prednisolone (triamcinolone acetone (Triamcinolon)), triamcinolone acetone -16 α, 17 α - acetonide (Qu acetonide (Triamcinolonacetonid)).

[0023] 在一个实施例中,所述的局部用产品,其特征在于其包含滋养与合成代谢物质L-脯氨酸。 [0023] In one embodiment, the topical product, characterized in that it comprises a nourishing substance with anabolic L- proline.

[0024] 在一个实施例中,所述的局部用产品,其特征在于其包含所述L-脯氨酸与一种或多种选自氨基酸、维生素与矿物质所组成群中的滋养与合成代谢物质的组合。 [0024] In one embodiment, the topical product, characterized in that it comprises the L- proline with one or more selected amino acids, the synthesis of trophoblast group consisting of vitamins and minerals metabolic combination of materials.

[0025] 在另一个实施例中,所述的局部用产品,其特征在于其包含所述L-脯氨酸与一种或多种选自:赖氨酸、半胱氨酸、明胶、生物素、泛酰醇、泛醇与无机或有机钙、镁或锌化合物的滋养与合成代谢物质的组合。 [0025] In another embodiment, the topical product, characterized in that it comprises the L- proline with one or more selected from the group: lysine, cysteine, gelatin, biological Su, panthenol, nourishing combination with panthenol anabolic substance with inorganic or organic calcium, magnesium or zinc compound.

[0026] 在一个实施例中,所述的局部用产品,其特征在于其包含一种或多种选自下列各物所组成群中的辅剂:萜烯或含萜烯的油、醇、酮、脂肪酸酯、聚乙二醇、表面活性剂、尿素、抗氧化剂与络合剂。 [0026] In one embodiment, the topical product, characterized in that it comprises one or more selected from the group consisting of the following composition adjuvants: a terpene or terpene-containing oils, alcohols, ketones, fatty acid esters, polyethylene glycol, a surfactant, urea, antioxidants and complexing agents.

[0027] 在另一个实施例中,所述的局部用产品,其特征在于其包含0.01至20重量%的一种或多种活性成份,I至99.99重量%的乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4-烷基酯,与O至98.99重量%辅剂。 [0027] In another embodiment, the topical product, characterized in that it comprises 0.01 to 20 weight percent of one or more active ingredients, I-99.99% by weight of lactic acid, malic acid, tartaric acid, citric acid, i ^ i ^ an acid or a carbon acid esters of C1-C4- alkyl, with O to 98.99% by weight of adjuvants.

[0028] 在一个实施例中,一种制备所述的局部用产品的方法,其特征在于均勻混合一种或多种乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4-烷基酯与可视需要选用的一种或多种辅剂,然后搅拌添加一种或多种活性成份至混合物中,可视需要加热溶解,并继续搅拌至形成均匀溶液为止。 [0028] In one embodiment, a method for the preparation of topical products, characterized in that the homogeneous mixing one or more lactic, malic, tartaric, citric, i ^ i ^ an acid or a carbon acid esters with C1-C4- alkyl optionally choose one or more adjuvants, followed by stirring of one or more active ingredients is added to the mixture, optionally dissolved by heating, and stirring is continued until formation until the solution was homogeneous.

[0029] 在另一个实施例中,一种制备所述局部用产品的方法,其特征在于所述的溶液中可添加其它生理上可兼容的调配辅剂,来制备所述局部用产品。 [0029] In another embodiment, a method for preparing the topical product, wherein said solution formulation adjuvants may be added to other physiologically compatible, preparing the topical product.

[0030] 本发明也涉及所述局部用产品在制备用于治疗、预防、后处理或支持性治疗疣、指甲疾病与甲周疾病的药物的应用。 [0030] The present invention also relates to the use of said topical product for the treatment, prevention, after-treatment or supportive treatment of warts, nail diseases and periungual diseases medicament.

[0031] 本发明进一步涉及所述的局部用产品在指甲保养上的应用。 [0031] The present invention further relates to the use of the products of the nail topical maintenance.

[0032] 本发明也进一步涉及所述的局部用产品在制备用于治疗宠物与家畜的蹄、爪与钩爪的霉菌感染的药物的应用。 [0032] The present invention further relates to a topical product in the shoe for the treatment of pets and livestock applications, claw finger fungal infections of the drug. [0033] 因此,本发明的目的在于解决与消除疣、局部治疗指甲疾病及局部保养指甲有关的问题,并提供一种可长期使用的医药与美容保养品。 [0033] Accordingly, an object of the present invention is to solve and eliminate warts, topical treatment of nail diseases and problems associated local nail care, and provides a pharmaceutical and beauty care products A long-term use.

[0034] 根据本发明一种无水的局部用产品,其可治疗疣,治疗指甲疾病及保养指甲,其组成如下: [0034] According to the present invention, an anhydrous topical products that treat warts, nail care and treatment of nail diseases, having the following composition:

[0035] a) 一种或多种活性成份, [0035] a) one or more active ingredients,

[0036] b)作为载剂的一种或多种乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4烷基酯,及 [0036] b) as a carrier of one or more of lactic, malic, tartaric, citric, i ^ i ^ an acid or a carbon acid esters of C1-C4 alkyl, and

[0037] c)可视需要选用的生理上可兼容的辅剂。 [0037] c) optionally physiologically compatible adjuvants selected.

[0038] 本发明无水的局部用产品基本上可采用所有可治疗疣、指甲与甲周疾病的合成与天然物质作为活性成分。 [0038] The present invention is substantially anhydrous topical products can be used to treat all warts, nail diseases and periungual synthetic and natural substances as active ingredients. 亦可使用可有效保养指甲的滋养与合成代谢物质作为活性成分。 It can also be used to nourish and nail care active anabolic substance as an active ingredient.

[0039] 根据本发明产品可包含的适当活性成分为抗霉菌剂(包括合成及天然来源者)、抗生素、抗菌剂、皮质类固醇、滋养与合成代谢物质,及其组合。 [0039] The product of the invention suitable active ingredient may comprise as antimycotic agents (including those synthetic and natural origin), antibiotics, antibacterial agents, corticosteroids, anabolic nourishing substances, and combinations thereof. 此等活性成分的特别实例为: Particular examples of such active ingredients as:

[0040]-抗霉菌剂与其生理上可兼容的盐类,如,例如:(±)_顺式_2,6- 二甲基-4-[2-甲基-3-(对-叔戍基-苯基)丙基]吗啉(安莫芬(Amorolfin))、两性霉素(Amphotericin)、6_ 环己基-1-轻基-4-甲基-2 (IH)-批P定酮(环匹罗司(Ciclopirox))、双-苯基-(2-氯苯基)-1-咪唑基甲烷(克霉唑(Clotrimazol))、1_[2_(2,4-二氯苯基)-2-(4-氯苯甲基氧)_乙基]-咪唑(益康唑(Econazol))、2,4-二氟-α,α-双(1H-1,2,4-三唑-1-基甲基)苯甲基醇(氟康唑(Fluconazol))、5-氟胞嘧啶(安确治(Flucytosin))、7-氯-三甲氧基-甲基螺_[苯并呋喃-环己烯]-二酮(灰黄霉素(Griseofulvin))、1-[2,4- 二氯- β - (2,6- 二氯苯甲基氧)-苯乙基]-咪唑(异康唑(Isoconazol))、(±)_ 1_ 仲丁基-4-{4_[4_(4-{[ (2R*,4S*)-2-(2,4- 二氯苯基)-2-(1, 2,4-三唑-1-基甲基)-1,3-二氧戊环-4-基]甲氧基}苯基)-1-哌嗪基]苯基}-4, 5- 二氢-1, 2, 4-三唑-5-酮(伊曲康唑(Itraconazol)),(±)顺式-1-乙酰基- [0040] - the antimycotic agent compatible with their physiological salts, such as, for example: (±) _ _2,6- cis-dimethyl-4- [2-methyl-3- (p - tert Shu yl - phenyl) propyl] morpholine (An Mofen (Amorolfin)), amphotericin (amphotericin), 6_ light-yl-1-cyclohexyl-4-methyl -2 (IH) - one batch of a given P ( ciclopirox (ciclopirox)), bis - phenyl - (2-chlorophenyl) -1-imidazol-yl methane (clotrimazole (clotrimazol)), 1_ [2_ (2,4- dichlorophenyl) - 2- (4-oxo-chlorobenzyl) _ ethyl] - imidazole (econazole (Econazol)), 2,4- difluoro -α, α- bis (1H-1,2,4- triazol - 1- ylmethyl) benzyl alcohol (fluconazole (Fluconazol)), 5- fluorocytosine (Ann determined rule (Flucytosin)), 7- chloro - trimethoxy - _ methyl spiro [benzofuran - cyclohexenyl] - dione (griseofulvin (griseofulvin)), 1- [2,4- dichloro - β - (2,6- dichlorobenzyl oxy) - phenethyl] - imidazole (iso itraconazole (Isoconazol)), (±) _ 1_ sec -4- {4_ [4_ (4 - {[(2R *, 4S *) - 2- (2,4- dichlorophenyl) -2- (1, 2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl] phenyl} -4, 5- dihydro-1, 2, 4-triazol-5-one (itraconazole (Itraconazol)), (±) cis-1-acetyl - 4-{4-([2-(2,4- 二氯苯基)-2-(1Η-咪唑-1-基甲基)-1,3- 二氧戊环_4_基]甲氧基)苯基}哌嗪(酮康唑(Ketoconazol))、1_[2,4_ 二氯-β - (2,4_ 二氯苯甲基氧)-苯乙基]-咪唑(咪康唑(Miconazol))、(E)-N-肉桂基-N-甲基_1_萘基甲基胺(萘替芬(Naftifin))、制霉菌素(Nystatin)、(E) -N-(6, 6-二甲基-2-庚烯-4-炔基)-N-甲基_1_萘基甲基胺(特比萘芬(Terbinafin))、1 [2-{(2-氯-3-噻吩基)甲氧基}-2-(2,4-二氯苯基)乙基]-1H-咪唑(噻康唑(Tioconazol))、0-2_萘基-N-甲基-N-(3-甲苯基)-硫代氨基甲酸酯(托萘酯(Tolnaftat))、α - (2,4_ 二氟苯基)_5_氟-β -甲基-α - (1Η-1,2,4_三唑-1-基甲基)-4-嘧啶乙醇(伏立康唑(Voriconazol)) ο 4- {4 - ([2- (2,4-dichlorophenyl) -2- (1Η- imidazol-1-ylmethyl) -1,3-dioxolan _4_ yl] methoxy ) phenyl} piperazine (ketoconazole (Ketoconazol)), 1_ [2,4_ dichloro -β - (2,4_-dichlorobenzyl oxy) - phenethyl] - imidazole (miconazole (Miconazol) ), (E) -N- methyl-cinnamyl--N- _1_ naphthylmethyl amine (naftifine (Naftifin)), nystatin (nystatin), (E) -N- (6, 6- dimethyl-2-hepten-4-ynyl) -N- methyl _1_ naphthylmethyl amine (terbinafine (Terbinafin)), 1 [2 - {(2- chloro-3-thienyl yl) methoxy} -2- (2,4-dichlorophenyl) ethyl] -1H- imidazole (tioconazole (Tioconazol)), 0-2_ naphthyl -N- methyl -N- ( 3-methylphenyl) - thiocarbamate (tolnaftate (Tolnaftat)), α - (2,4_-difluorophenyl) _5_ [beta] -D-fluoro - methyl -α - (1Η-1,2, 4_ triazol-1-ylmethyl) -4-pyrimidinyl ethanol (voriconazole (Voriconazol)) ο

[0041]-天然抗霉菌剂,如,例如:芳香精油与植物抽出物。 [0041] - Natural antimycotic agents, such as, for example: aromatic essential oils and plant extractives.

[0042]-抗生素与其生理上可兼容的盐类,如,例如:α-氨基-4-羟基苯甲基青霉素(羟氨苄青霉素(Amoxicillin))、D-(-)-a-氨基苯甲基青霉素(氨苄青霉素(Ampicillin))、3,3- 二甲基-7-氧代-6-苯基乙酰胺基-4-硫杂-1-氮杂双环-[3.2.0]-庚烷-2-羧酸(节青霉素(Benzylpenicillin))、节青霉素-节星(Benzylpenicillin-benzathin)、3-氯-7-D (2-苯基甘胺氨酸氨基)-头孢酸(头孢克洛(Cefaclor))、7 β - [D_2_氨基-(4-轻基-苯基)-乙酰氨基]-3_甲基-头孢酸(头孢轻氨(Cefadroxil))、氨基苯基-乙酰氨基-甲基-头孢酸(头孢氨苄(Cefalexin))、D(-)_对-2-二氯乙酰氨基-1- (4-硝基苯基)-1, 3-丙二醇(氯霉素(Chloramphenicol)、1-环丙基_6_ 氟-1,4- 二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸(环丙沙星(Ciprofloxacin))、(Z) - (2R,5R)-3-(2-羟基亚乙基)-7-氧代-4-氧杂-1-氮杂双环[3.2.0]庚烷_2_羧酸(克拉维酸(Clavulanic acid))、7_氯-7-脱氧-林可霉素(氯林可霉素(Clindamycin [0042] - Antibiotics its physiologically compatible salts such as, for example: α- amino-4-hydroxybenzyl penicillins (amoxicillin (Amoxicillin)), D - (-) - a- amino benzyl penicillin (ampicillin (ampicillin)), 3,3- dimethyl-7-oxo-6-phenyl-acetamido-4-thia-1-azabicyclo - [3.2.0] - heptane - acid 2- (section penicillin (Benzylpenicillin)), penicillin section - section Star (Benzylpenicillin-benzathin), 3- chloro -7-D (2- amine-phenylglycine amino acid) - cephem acid (cefaclor (cefaclor )), 7 β - [D_2_ amino - (light 4- yl - phenyl) - acetylamino] methyl -3_ - cephem acid (cephalosporin light ammonia (Cefadroxil)), amino phenyl - acetamido - methyl - cephalosporin acid (cephalexin (cefalexin)), D (-) _ of dichloroacetyl -2- amino-1- (4-nitrophenyl) -1,3-propanediol (chloramphenicol (chloramphenicol), 1 - cyclopropyl _6_ dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (ciprofloxacin (ciprofloxacin)), (Z) - (2R, 5R) -3- (2- hydroxyethylidene) -7-oxo-4-oxa-1-azabicyclo [3.2.0] heptane-_2_ acid (clavulanic acid (clavulanic acid)), 7_-chloro-7-deoxy - lincomycin (clindamycin (clindamycin ))、6_去氧-5-轻基四环素(强力霉素(Doxycyclin))、1_乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)_1,8-萘卩定-3-羧酸(依诺沙辛(Enoxacin))、红霉素、3-(2-氯-6-氟苯基)-5_甲基-4-异恶唑基-青霉素(氟氯西林(Flucloxacillin))、卡那霉素(Kanamycin)、林可霉素(Lincomycin)、7-二甲基氨基-6-脱氧-6-去甲基四环素(二甲胺四环素(Minocyclin))、6- (2-乙氧基-1-萘酰胺基)-青霉素(萘夫西林(Naf ci I Iin)), 1-乙基-1,4- 二氢-7-甲基-4-氧代-1,8-萘唳-3-羧酸(萘唳酮酸(Nalidixic acid))、新霉素(Neomycin)、1-乙基_6_氟-1,4- 二氢-4-氧代-7- (1-哌嗪基)-3-喹啉羧酸(诺氟沙星(Norfloxacin))、(±)-9_氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[I, 2,3-de][I, 4]苯并恶嗪-6-羧酸(氧氟沙星(Ofloxacin))、6_(5-甲基-3-苯基-4-异恶唑羧酰胺基)青霉烷酸(甲苯异恶唑青霉素(Oxacillin) )、6_苯氧基乙酰氨基-青霉烷酸(苯氧基甲基青霉素)、4_ )), Light-yl 6_ deoxy -5- tetracycline (doxycycline (Doxycyclin)), 1_-ethyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl yl) naphthalene Jie _1,8- given 3-carboxylic acid (by Nuosha Xin (Enoxacin)), erythromycin, 3- (2-chloro-6-fluorophenyl) -4-methyl -5_ oxazolyl - penicillin (flucloxacillin (flucloxacillin)), kanamycin (kanamycin), lincomycin (lincomycin), 7- dimethylamino-6-deoxy-6-demethyl-tetracycline (dimethyl amine tetracycline (Minocyclin)), 6- (2- ethoxy-1-naphthyl amide yl) - penicillin (nafcillin (Naf ci I Iin)), 1- ethyl-1,4-dihydro-7- methyl-4-oxo-1,8-naphthyridine-3-carboxylate Li (Li naphthalene acid (nalidixic acid)), neomycin (neomycin), 1- ethyl-1,4-difluoro-_6_ dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (norfloxacin (norfloxacin)), (±) -9_ fluoro-2,3-dihydro-3 - methyl-10- (4-methylpiperazin-1-piperazinyl) -7-oxo -7H- pyrido [I, 2,3-de] [I, 4] benzoxazine-6-carboxamide acid (ofloxacin (ofloxacin)), 6_ (5- methyl-3-phenyl-4-isoxazole carboxamide yl) penicillanate (toluene-isoxazolyl penicillin (Oxacillin)), 6_ benzene oxy acetamido - penicillanic acid (phenoxymethyl penicillin), 4 _ 甲基胺基-八氢-五羟基-1,11- 二氧代-6-甲基-萘并萘-2-脲(四环素)。 Methylamino - octahydro - five-1,11-dioxo-6-methyl - urea naphthalene and naphthalene-2 ​​(tetracycline).

[0043]-抗菌剂,如,例如:烧基苯甲基二甲基氯化铵(苯扎氯铵(Benzalkoniumchloride))、N-苯甲基-N, N-二甲基_2-{2_[对-(1,I, 3, 3-四甲基丁基)-苯氧基]-乙氧基}-乙基氢氧化铵(氯化节乙氧铵(benzethonium chloride))、鲸腊基三甲基氢氧化铵(西曲溴铵(Cetrimonium bromid) )、1,I' _六亚甲基-双-[5-(对氯苯基)-双缩胍](洗必泰(Chlorhexidin))、N1, N1-十亚甲基-双_(4_氨基甲基喹哪唳鐵氢氧化物)(克菌定(Dequalinium chlorid))、N-(4_ 氯苯基)-N' _(3,4-二氯苯基)脲(三氯二苯脲(Triclocarbane))、5-氯-2-(2, 4-二氯苯氧基)苯酹(三氯生(Triclosan))。 [0043] - an antibacterial agent, such as, for example: burning benzyl dimethyl ammonium chloride (benzalkonium chloride (Benzalkoniumchloride)), N- benzyl -N, N- dimethyl-_2- {2_ [p - (1, I, 3, 3- tetramethylbutyl) - phenoxy] - ethoxy} - ethyl ammonium hydroxide (v benzethonium chloride (benzethonium chloride)), cetyl group trimethyl ammonium hydroxide (cetrimide (cetrimonium bromid)), 1, I '_ hexamethylene - bis - [5- (p-chlorophenyl) - biguanide] (chlorhexidine (Chlorhexidin) ), N1, N1- decamethylene - _ bis (aminomethyl quinoline 4_ which Li iron hydroxide) (dequalinium (dequalinium chlorid)), N- (4_ chlorophenyl) -N '_ ( 3,4-dichlorophenyl) urea (triclocarban (Triclocarbane)), 5- chloro-2- (2,4-dichlorophenoxy) phenyl sprinkle (triclosan (triclosan)).

[0044]-皮质类固醇与其生理上可兼容的盐类,如,例如:9 α -氯-16 β -甲基氢化波尼松(倍氯米松(Beclo methason))、9_氟-11 β,17,21-三轻基-16 β -甲基_1,4-孕二稀-3,20- 二丽(倍他米松(Betamethason)) >21-氣-9-氣_11β,17-二羟基-16 β -甲基-1,4-孕二烯-3,20- 二酮(氯倍米松(Clobetasol))、17,21- 二羟基-孕-4-烯-3,11,20-三酮(可的松(Cortisone))、11 β,16 α , 17 α,21-四羟基-1,4-孕二烯-3,20- 二酮-16,17-丙酮缩醛(丙缩羟强龙(Desonid))、9_氟-11 β -17,21-三羟基-16 α -甲基孕留-1, 4- 二烯-3,20- 二酮(地塞米松(Dexamethason) )、9α,11β -二氯-6 α -氟-21-羟基-16 α,17 α -(异亚丙基二氧)-孕甾-1,4- 二烯-3,20- 二酮(氟氯奈德(Flucloronid))、6 α,9 α - 二氟-16 α,17 α -异亚丙基二氧-皮质酮(肤轻松(Fluocinolonacetonid) )、6α,9α -二氟-16 α, 17 α -异亚丙基二氧-皮质酮-乙酸盐(醋酸氟轻松(Fluocinonind))、6 α [0044] - a corticosteroid compatible with their physiological salts, such as, for example: 9 α - chloro -16 β - methyl prednisolone (beclomethasone (Beclo methason)), 9_ fluoro -11 β, 17,21 three light-yl -16 β - methyl-diene-3,20-two pregnant _1,4- Li (betamethasone (Betamethason))> 21- gas -9- gas _11β, 17- two hydroxy -16 β - methyl-1,4-pregnadiene-3,20-dione (betamethasone chloro-fold (Clobetasol)), 17,21- dihydroxy - pregn-4-ene -3,11,20- trione (cortisone (cortisone)), 11 β, 16 α, 17 α, 21- tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-acetal with acetone (prop-condensing Long-hydroxybutyl (Desonid)), 9_ fluoro -11 β -17,21- trihydroxy -16 α - methyl pregnancy left-1,4-diene-3,20-dione (dexamethasone (dexamethason) ), 9α, 11β - dichloro -6 α - fluoro-21-hydroxy--16 α, 17 α - (isopropylidene-dioxy) - pregna-1,4-diene-3,20-dione ( fluclorolone acetonide (Flucloronid)), 6 α, 9 α - difluoro -16 α, 17 α - isopropylidene-dioxo - corticosterone (fluocinolone (Fluocinolonacetonid)), 6α, 9α - difluoro -16 α , 17 α - isopropylidene-dioxo - corticosterone - acetate (fluocinolone (Fluocinonind)), 6 α -氟-11 β,21- 二轻基-6 α,17-异亚丙基二氧-4-孕烯-3,20- 二酮(氟氢缩松(Fludroxycortid))、3_(2_氯乙氧基)-9 α -氟-6-甲酰基-11 β,21- 二羟基-16 α,17 α -异亚丙基二氧孕-3,5- 二烯-20-酮(福莫可他(Formocortal)) >21-氯_9 α -氟-11 β -轻基-16 α,17 α -异亚丙基二氧-4-孕烯-3,20-二酮(哈西萘德(Halcinonid) )、17 α-羟基皮质酮(氢化可的松(Hydrocortison))、11 β,17, 21-三轻基-6 α -甲基-1, 4-孕二烯-3,20-二酮(甲基氢化泼尼松(Methylprednisolon))、11 β,17, 21-三轻基-孕-1, 4- 二烯-3, 20- 二酮(强的松龙(Prednisolon))、17 α,21- 二轻基-孕-1, 4- 二烯-3, 11, 20-三酮(泼尼松(Prednison))、9-氟-16α-羟基氢化泼尼松(丙酮氟羟泼尼松龙(Triamcinolon))、丙酮氟羟泼尼松龙-16 α,17 α -丙酮化物(曲安奈德(Triamcinolonacetonid))。 - fluoro -11 β, 21- two light-yl -6 α, 17- isopropylidene-dioxo-4- pregnene-3,20-dione (flurandrenolide (Fludroxycortid)), 3_ (2_ chloro ethoxy) -9 α - fluoro-6-formyl -11 β, 21- dihydroxy -16 α, 17 α - isopropylidene-dioxo-3,5-dien-20-one progestin (formoterol he (Formocortal))> 21- chloro _9 α - fluoro -11 β - light-yl -16 α, 17 α - isopropylidene-dioxo-4- pregnene-3,20-dione (hash naphthalene de (Halcinonid)), 17 α- hydroxy corticosterone (hydrocortisone (Hydrocortison)), 11 β, 17, 21- three light-yl -6 α - methyl-1, 4-pregnene -3,20-diene - dione (methylprednisolone (Methylprednisolon)), 11 β, 17, 21- three light-yl - pregnancy-1,4-diene -3, 20-dione (prednisolone (prednisolon)) , 17 α, 21- two light-yl - pregnancy-1,4-diene -3, 11, 20- trione (prednisone (Prednison)), 9- fluoro-prednisolone-hydroxy -16α- (acetone-fluoro triamcinolone (Triamcinolon)), triamcinolone acetone -16 α, 17 α - acetonide (triamcinolone acetonide (Triamcinolonacetonid)).

[0045] 滋养与合成代谢物质,例如,2-吡咯烷羧酸(L-脯氨酸)。 [0045] The trophoblast anabolic substance, e.g., 2-pyrrolidin-carboxylic acid (L- proline). 根据本发明较佳抗霉菌剂为双-苯基-(2-氯苯基)-1-咪唑基甲烷(克霉唑(Clotrimazol))、1-[2,4- 二氯- β-(2,6-二氯苯甲基氧)_苯乙基]-咪唑(异康唑(Isoconazol))、2,4- 二氟-α,α-双(1!1-1,2,4-三唑-1-基甲基)苯甲基醇(氟康唑(Fluconazol))、(±)-1-仲丁基-4- {4- [4- (4- {[ (2R*,4S*) -2- (2,4- 二氯苯基)~2~ (I, 2,4_ 三唑-1-基甲基)-1,3- 二氧戊环-4-基]甲氧基}苯基)-1-哌嗪基]苯基}-4,5-二氢-1,2,4-三唑-5-酮(伊典康唑(Itraconazol))、(±)顺式-1-乙酰基-4- {4- ([2- (2,4- 二氯苯基)-2- (1H-咪唑-1-基甲基)-1, 3- 二氧戍环-4-基]甲氧基)苯基}哌嗪(酮康唑(Ketoconazol))、1-[2,4- 二氯- β - (2,4- 二氯苯甲基氧)-苯乙基]-咪唑(咪康唑(Miconazol))、(E)-N-(6, 6_ 二甲基-2-庚烯-4-炔基)-N-甲基-1-萘基甲基胺(特比萘芬(Terbinafin) )、α-(2,4_ 二氟苯基)-5-氟- β-甲基- α - (1Η-1,2,4-三唑-1-基甲基)-4-嘧啶乙醇(伏立康唑(Voriconazo According to the present invention, the preferred antimycotic agent is bis - phenyl - (2-chlorophenyl) -1-imidazol-yl methane (clotrimazole (Clotrimazol)), 1- [2,4- dichloro - β- (2 , 6-oxo-dichlorobenzyl) _ phenethyl] - imidazole (isoconazole (Isoconazol)), 2,4- difluoro -α, α- bis (1 1-1,2,4 three! -1-ylmethyl) benzyl alcohol (fluconazole (Fluconazol)), (±) -1- sec -4- {4- [4- (4- {[(2R *, 4S * ) -2- (2,4-dichlorophenyl) ~ 2 ~ (I, 2,4_-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl] phenyl} -4,5-dihydro-1,2,4-triazol-5-one (Yidian itraconazole (Itraconazol)), (±) cis-1 - acetyl-4- {4- ([2- (2,4-dichlorophenyl) -2- (1H- imidazol-1-ylmethyl) -1,3-dioxo-4-yl Shu ] methoxy) phenyl} piperazine (ketoconazole (Ketoconazol)), 1- [2,4- dichloro - beta] - (2,4-dichlorobenzyl oxy) - phenethyl] - imidazole (miconazole (Miconazol)), (E) -N- (6, 6_ hept-dimethyl-2-en-4-yn-yl) -N- methyl-1-naphthylmethyl amine (terbinafine Fen (Terbinafin)), α- (2,4_-difluorophenyl) -5-fluoro - β- methyl - α - (1Η-1,2,4- triazol-1-ylmethyl) -4- pyrimidine in ethanol (voriconazole (Voriconazo l))。 l)).

[0046] 根据本发明较佳抗霉菌剂为双-苯基-(2-氯苯基)-1_咪唑基甲烷(克霉唑(Clotrimazol))、1_[2,4- 二氯- β - (2,6- 二氯苯甲基氧)-苯乙基]-咪唑(异康唑(Isoconazol))、(±)-1-仲丁基_4_{4_[4_(4_{[ (2R*,4S*)_2_(2,4-二氯苯基)-2-(1, 2,4-三唑-1-基甲基)-1,3-二氧戊环-4-基]甲氧基}苯基)-1-哌嗪基]苯基}-4,5- 二氢-1, 2, 4-三唑-5-酮(伊典康唑(Itraconazol))、(±)顺式-1-乙酰基-4- {4- ([2- (2,4- 二氯苯基)-2- (1H-咪唑-1-基甲基)-1, 3- 二氧戊环_4_基]甲氧基)苯基}哌嗪(酮康唑(Ketoconazol))。 [0046] According to the present invention, the preferred antimycotic agent is bis - phenyl - (2-chlorophenyl) -1_ imidazolyl methane (clotrimazole (Clotrimazol)), 1_ [2,4- dichloro - beta] - (2,6-dichlorobenzyl oxy) - phenethyl] - imidazole (isoconazole (Isoconazol)), (±) -1- sec _4_ {4_ [4_ (4 _ {[(2R * , 4S *) _ 2_ (2,4- dichlorophenyl) -2- (1, 2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy yl} phenyl) -1-piperazinyl] phenyl} -4,5-dihydro-1, 2, 4-triazol-5-one (Yidian itraconazole (Itraconazol)), (±) cis -1-acetyl-4- {4- ([2- (2,4-dichlorophenyl) -2- (1H- imidazol-1-ylmethyl) -1,3-dioxolan _4 _-yl] methoxy) phenyl} piperazine (ketoconazole (Ketoconazol)).

[0047] 较佳天然抗霉菌剂为茶树·油(Melaleuca alternifolia)、熏衣草油(Lavandulaofficinalis chaix)和印楝树提取物(Azadirachta indica)。 [0047] The antimycotic agent is preferably a natural tea-oil (Melaleuca alternifolia), lavender oil (Lavandulaofficinalis chaix) and extract neem tree (Azadirachta indica). 此等天然抗霉菌剂可单独作为活性成分使用或与其它多种此等活性成分组合使用。 These natural antimycotic agent may be used alone or as an active ingredient used in combination with other ingredients for such activity, and more. 较佳活性成分组合为熏衣草油、茶树油和印楝树提取物,且特别是金钟柏油用于消除疣。 Preferred compositions the active ingredient extract is lavender oil, tea tree oil and neem tree, thuja oil, and particularly for removing warts. 较佳抗菌剂为如,例如:1,I'-六亚甲基-双-[5_(对-氯苯基)_双缩胍](洗必泰(Chlorhexidin))。 The preferred antimicrobial agent is, for example: 1, I'- hexamethylene - bis - [5_ (p - chlorophenyl) _ biguanide] (Chlorhexidine (Chlorhexidin)).

[0048] 较佳皮质类固醇为11 β,16 α,17 α,21-四羟基-1,4-孕二烯-3,20- 二酮-16,17-丙酮缩醛(丙缩羟强龙(Desonid))、9α,11 β -二氯-6 α -氟-21-羟基-16 α,17α-(异亚丙基二氧)-孕留-1, 4_ 二烯_3,20- 二酮(氟奈德(Flucloronid))、6 α,9 α - 二氟-16 α, 17 α -异亚丙基二氧-皮质酮(肤轻松(Fluocinolonacetonid) )、6α,9α -二氣-16 ct, 17 α -异亚丙基二氧-皮质丽-乙酸盐(醋酸氟轻松(Fluocinonind))、6 α -氟-11 β,21- 二轻基-6 α,17-异亚丙基二氧-4-孕烯-3,20- 二酮(氟氢缩松(Fludroxycortid))、3-(2-氯乙氧基)_9 α -氟-6-甲酰基-11 β,21- 二羟基-16 α,17 α -异亚丙基二氧孕-3,5- 二烯_20_酮(福莫可他(Formocortal)) >21-氯-9 α -氟-11 β -轻基-16 α, 17 α -异亚丙基二氧-4-孕烯-3,20- 二酮(哈西萘德(Halcinonid))、氢羟强的松龙-16 α,17 α -丙酮化物(曲安奈德(Triamcinolonacetonid))ο [0048] The preferred corticosteroid is 11 β, 16 α, 17 α, 21- tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-acetal with acetone (prop-hydroxyethyl condensing prednisolone (Desonid)), 9α, 11 β - dichloro -6 α - fluoro-21-hydroxy--16 α, 17α- (isopropylidene-dioxy) - pregnant left -1, 4_ two diene _3,20- one (fluoro Ned (Flucloronid)), 6 α, 9 α - difluoro -16 α, 17 α - isopropylidene-dioxo - corticosterone (fluocinolone (Fluocinolonacetonid)), 6α, 9α - two gas -16 ct, 17 α - isopropylidene-dioxo - Li cortex - acetate (fluocinolone (Fluocinonind)), 6 α - fluoro -11 β, 21- two light-yl -6 α, 17- isopropylidene dioxo-4- pregnene-3,20-dione (flurandrenolide (Fludroxycortid)), 3- (2- chloroethoxy) _9 α - fluoro-6-formyl -11 β, 21- two hydroxy -16 α, 17 α - isopropylidenedioxy-3,5-diene-_20_ one progestin (formocortal (formocortal))> 21- chloro -9 α - fluoro -11 β - light-yl -16 α, 17 α - isopropylidene-dioxo-4- pregnene-3,20-dione (naphthalene de hash (Halcinonid)), hydrocortisone prednisolone -16 α, 17 α - acetonide (triamcinolone acetonide (Triamcinolonacetonid)) ο

[0049] 活性成份的特殊组合实例为: Examples of specific compositions [0049] The active ingredient is:

[0050] 皮质类固醇与抗霉菌剂、抗生素或抗菌剂的组合。 Corticosteroid [0050] with antimycotic agents, antibiotic or antibacterial agent. 较佳组合为例如:(±)顺式-1-乙酰基-4-{4-([2-(2,4- 二氯苯基)-2-(1Η-咪唑-1-基甲基)_1,3_ 二氧戊环-4-基]甲氧基)苯基}-哌嗪(酮康唑(Ketoconazol))与11 β,16 α,17 α,21-四轻基-1,4-孕二烯-3,20- 二酮-16,17-丙酮缩醛(丙缩羟强龙(Desonid))的组合。 Preferably, for example, a combination of: (±) cis-1-acetyl-4- {4 - ([2- (2,4-dichlorophenyl) -2- (1Η- imidazol-1-ylmethyl) _1,3_ dioxolan-4-yl] methoxy) phenyl} - piperazine (ketoconazole (Ketoconazol)) and the 11 β, 16 α, 17 α, 21- four light-1,4 pregnadiene-3,20-dione 16,17-acetal with acetone composition (prop-hydroxyethyl condensing prednisolone (Desonid)) of.

[0051] 合成性抗霉菌剂与天然抗霉菌剂的组合。 Combination of [0051] synthetic antimycotic agents and natural anti-fungal agent. 较佳组合为双-苯基-(2-氯-苯基)-1-咪唑基甲烷(克霉唑(Clotrimazol))与茶树精油的组合。 Preferred combination is bis - phenyl - (2-chloro - phenyl) -1-imidazol-yl methane (clotrimazole (clotrimazol)) and a combination of tea tree oil.

[0052] 各种不同天然抗霉菌剂的组合。 Composition [0052] The various natural antimycotic agents. 较佳组合为熏衣草油、茶树精油、印楝树提取物(Azadirachta indica)与ABC 油(澳洲蓝柏树油(Australian Blue Cypress Oil))和金钟柏油的组合。 Preferred combination is lavender oil, tea tree oil, extracts of neem tree (Azadirachta indica) oil in combination with ABC (Australian Blue Cypress oil (Australian Blue Cypress Oil)) and thuja oil.

[0053] 2-吡咯烷羧酸(L-脯氨酸)与一种或多种选自下列各物组成的群中的其它滋养与合成代谢物质的组合:氨基酸、维生素与矿物质。 [0053] 2-pyrrolidin-carboxylic acid (L- proline) combination with one or more other nourishing and anabolic substances selected from the group consisting of the following composition and a: amino acids, vitamins and minerals.

[0054] 2-吡咯烷羧酸(L-脯氨酸)与一种或多种滋养与合成代谢物质的较佳组合为与 [0054] 2-pyrrolidin-carboxylic acid (L- proline) preferably in combination with one or more nourishing and anabolic substance with the

(S) -2,6- 二氨基己酸(赖氨酸)、(R) -2-氨基-3-氢硫基丙酸(半胱氨酸(cystein))、明胶、顺式-2-(4-羧基丁基)-3,4-脲基四氢噻吩(生物素)、(±) 2,4-二羟基-N-(3-羟基丙基)-3,3- 二甲基丁酸(泛酰醇)、D (+) -2,4- 二羟基-N- (3-羟基丙基)_3,3- 二甲基丁酸(泛醇)与无机或有机钙、镁或锌化合物的组合。 (S) -2,6- diamino acid (lysine), (R & lt) -2- amino-3-mercapto propionic acid (cysteine ​​(cystein)), gelatin, cis-2 (4-carboxy-butyl) -3,4-ureido tetrahydrothiophene (biotin), (±) 2,4- dihydroxy -N- (3- hydroxypropyl) -3,3- acid (panthenol), D (+) -2,4- dihydroxy -N- (3- hydroxypropyl) _3,3--dimethyl butyric acid (panthenol) with inorganic or organic calcium, magnesium or zinc combination of compounds.

[0055] L-脯氨酸为特别适合指甲合成代谢与指甲保养的合成代谢物质。 [0055] L- proline is particularly suitable for synthetic anabolic metabolites nail nail maintenance. L-脯胺酸目前仅为指甲保养品视需要选用的组成份,作为包含含硫氨基酸或含硫氨基酸的衍生物的活性成分(ΕΡ-Α-0 534 810) 。 L- proline currently only parts nail care products consisting of optionally selected, as an active ingredient comprising a sulfur-containing amino acids or sulfur-containing amino acid derivative (ΕΡ-Α-0 534 810).

[0056] 上述物质在下文中是以上文中括号内名称表示的相应名称代表。 [0056] The foregoing is representative of the corresponding name in parentheses indicates the name described in the above hereinafter.

[0057] 作为载剂使用的C1-C4-烷基酯包括甲酯、乙酯、正丙酯、异丙酯、正丁酯、仲丁酯、异丁酯、与叔丁酯。 [0057] C1-C4- alkyl esters for use as a carrier include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl. 多碱价酸类:苹果酸、柠檬酸与酒石酸的酯类中,其酯基所包含(;-(;-烷基可相同或相异。如上述多碱价酸类可由所有羧酸根或部份羧酸根进行酯化。除了苹果酸与酒石酸二-C1-C4-烷基酯以外,亦可使用相应的苹果酸与酒石酸单烷基酯。适用的柠檬酸的C1-C4-烷基酯为相应的单-、二-与三烷基酯。较佳酯类为乙酯。其它较佳酯类为异丙基酯。较佳单一化合物为乳酸乙酯。其它较佳单一化合物为苹果酸二乙基酯与苹果酸二异丙基酷。 Polybasic acids: malic acid, tartaric acid and citric acid esters in which the ester group contained in (; - (; - may be the same or different alkyl group as described above polybasic acids may be all or part carboxylate. parts esterified carboxylate Apart of malic acid and tartaric acid -C1-C4- alkyl esters, can also be used with the corresponding tartaric malic acid monoalkyl esters. suitable C1-C4- alkyl esters of citric acid corresponding mono -, di - and trialkyl esters are preferred other acrylate esters are preferably isopropyl ester is preferably ethyl lactate single compound other preferred single compound is malic acid... ethyl ester and isopropyl malate cool.

[0058] 本发明局部用产品除了一种或多种活性成份与作为载剂的一种或多种乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4-烷基酯外,尚可包含生理上可相容的辅剂。 [0058] The present invention is a topical product in addition to one or more of the active ingredient with one or more lactic acid as carrier agents, malic acid, tartaric acid, citric acid, a i ^ i ^ alkanoic acid or a carbon acid C1 outer -C4- alkyl ester, comprising a physiologically acceptable compatible adjuvants. 适当辅剂为例如:萜烯或含萜烯的油、醇、酮、脂肪酸酯、聚乙二醇、表面活性剂、尿素、抗氧化剂与络合剂。 Suitable adjuvants, for example: terpenes or terpene-containing oils, alcohols, ketones, fatty acid esters, polyethylene glycol, a surfactant, urea, antioxidants and complexing agents.

[0059] 适合的萜烯为无环、单环与双环萜烯及含此等萜烯的油类。 [0059] Suitable acyclic terpenes, monocyclic and bicyclic terpenes and terpene containing these oils. 无环系萜烯实例为无环系萜烯烃类,如,例如:香叶烯,无环萜烯醇,如,例如:香茅醇与牛儿醇,及无环系萜烯醛与-酮,如,例如:柠檬醛、α-紫罗酮与β_紫罗酮。 Examples of terpene-based non alkenyl ring system acyclic terpene hydrocarbons, such as, for example: myrcene, acyclic terpene alcohols, such as for example: citronellol and geraniol, and system acyclic terpene aldehyde and - one , such as, for example: citral, ionone alpha] and β_ ionone. 单环萜烯实例为单环萜烯烃类,如,例如:α-萜品、Y-萜品与苎烯、单环萜烯醇,如,例如:百里酚、薄荷醇、桉树脑与香芹酚,及单环萜烯酮,如,例如:薄荷酮与香芹酮。 Examples of monocyclic terpene monocyclic terpene hydrocarbons, such as, for example: alpha] terpineol, Y- terpinene and limonene, monocyclic terpene alcohols, such as, for example: thymol, menthol, eucalyptol and Hong Qin phenol, and a monocyclic terpene ketones, such as for example: menthone and carvone. 双环萜烯实例为蒈烷类萜烯,如,例如:蒈酮,菔烷类職烯,如,例如:α-菔烯与β -菔烯,及冰片烧类職烯,如,例如:樟脑与冰片。 Examples of bicyclic terpene carane terpenoid such as, for example: carone, turnip alkenyl functional alkanes, such as, for example: alpha] turnip alkylene β - ethylenically turnip, borneol and grades in burn alkenyl, such as, for example: camphor and borneol. 特别适合的萜烯为单环萜烯醇,如,例如:百里酚与薄荷醇。 Particularly suitable terpenes are monocyclic terpene alcohols, such as, for example: menthol and thymol. 适合的含萜烯的油类实例为薄荷油、小宣蘧油、香叶油、玫瑰精油、金钟柏油与百里油。 Examples of suitable oils containing terpenes as peppermint, Xuan Qu small oil, geranium oil, rose oil, thuja oil and thyme oil. 特别适合的油类为薄荷油、熏衣草油与百里油。 Particularly suitable as peppermint oil, lavender oil and thyme oil. 如上述,金钟柏油特别适合用于消除疣。 As described above, thuja oil is particularly suitable for removing warts.

[0060] 适合的醇为具有I至3个羟基与2至6个碳原子的分支或未分支的醇,其中羟基可部份或完全醚化或酯化。 [0060] Suitable alcohols are branched or unbranched with I to 3 alcoholic hydroxyl groups of from 2 to 6 carbon atoms, wherein the hydroxyl groups may be partially or completely etherified or esterified. 特别合适的醇类为乙醇、1-丙醇、2-丙醇(异丙醇)、1,2_丙二醇(丙二醇)、2_苯基乙醇(苯基乙醇)、1_ 丁醇(丁醇)、乙二醇单甲基醚(甲氧基乙醇)、乙二醇单苯基醚(苯氧基乙醇)、1,2,3-三羟基丙烷(甘油)、乙酸乙酯、乙酸丁酯、二乙酸甘油酯(二醋精)与三乙酸甘油酯(三醋精)。 Particularly suitable alcohols are ethanol, 1-propanol, 2-propanol (isopropanol), 1,2_-propanediol (propylene glycol), 2_ phenylethanol (phenylethanol), 1_ butanol (butanol) , ethylene glycol monomethyl ether (methoxy ethanol), ethylene glycol monophenyl ether (phenoxyethanol), 1,2,3-trihydroxy propane (glycerol), ethyl acetate, butyl acetate, glycerol diacetate (diacetin) and glycerol triacetate (triacetin).

[0061] 合适的酮实例为丙酮与甲基乙基酮(2-丁酮)。 [0061] Examples of suitable ketones are acetone and methyl ethyl ketone (2-butanone).

[0062] 脂肪酸酯为饱和与未饱和,分支与未分支的8至21个碳原子脂肪酸的酯类,其醇成份包含I至6个碳原子的分支与未分支醇类。 [0062] The fatty acid esters are saturated and unsaturated, 8-21 carbon atoms, fatty acid esters of branched and unbranched, whose alcohol components contain I to 6 carbon atoms, branched and unbranched alcohols. 特别适合的脂肪酸酯为十三烷羧酸异丙基酯、十四烷羧酸异丙基酯(肉宣蘧酸异丙酯)、十五烷羧酸甲酯与9-十八烯酸甘油单酯(甘油单油酸酯(glycerin monooleate))。 Particularly suitable fatty acid ester is a carboxylic acid isopropyl ester tridecane, tetradecane carboxylic acid isopropyl ester (isopropyl myristate meat declared Qu), pentadecanoic acid methyl ester with 9-octadecenoic acid monoglyceride (glycerol monooleate (glycerin monooleate)).

[0063] 合适的聚乙二醇为例如:聚乙二醇400。 [0063] Suitable polyethylene glycols are for example: polyethylene glycol 400.

[0064] 合适的表面活性剂为例如:非离子性界面活性成份。 [0064] Suitable surfactants are, for example: non-ionic surface active ingredient. 特别合适的表面活性剂为山梨糖醇酐的部份脂肪酸酯(Span)、聚氧乙烯山梨糖醇酐的部份脂肪酸酯(Tween)、聚氧乙烯的脂肪酸酯(Myrj)与聚氧乙烯的脂肪醇醚(Brij)。 Particularly suitable surfactants are sorbitan fatty acid partial esters of sorbitan (Span), polyoxyethylenesorbitan fatty acid partial esters of sorbitan (Tween), polyoxyethylene fatty acid esters (Myrj) and poly polyoxyethylene fatty alcohol ethers (Brij).

[0065] 合适的抗氧化剂为例如:丁基羟基甲苯(BHT)、丁基-4-甲氧基苯酚(BHA)、生育酚与抗坏血酸。 [0065] Suitable antioxidants are, for example: butyl hydroxy toluene (BHT), butyl-4-methoxyphenol (BHA), ascorbic acid and tocopherol.

[0066] 合适的络合剂为例如:乙二胺四乙酸(EDTA)与乙二胺四乙酸二钠(Na2-ETDA)。 [0066] Suitable complexing agents, for example: ethylenediaminetetraacetic acid (EDTA) and disodium edetate (Na2-ETDA).

[0067] 根据本发明局部用·产品可呈例如:溶液、酊剂、乳液、凝胶、软膏、乳霜与糊剂。 [0067] for example, it may be in the topical-product according to the present invention: solutions, tinctures, emulsions, gels, ointments, creams and pastes. 较佳局部施药型式为溶液。 Topical application solution type is preferred.

[0068] 本发明亦有关一种制备本发明局部用产品的方法,其特征在于均匀混合乳酸乙酯与一种或多种辅剂,然后搅拌添加一种或多种活性成分至混合物中,可视需要加热(最高80°C),继续搅拌至得到均匀溶液为止。 [0068] The present invention also relates to a process for the preparation of topical products of the invention, wherein ethyl lactate uniformly mixed with one or more adjuvants, followed by stirring addition of one or more active ingredients to the mixture, can be optionally heating (up to 80 ° C), stirring is continued until homogeneous solution was obtained. 所得溶液最好直接用于局部施药。 The resulting solution is preferably used directly for topical application. 然而,该溶液亦可添加其它生理上可兼容的调配辅剂,利用已知的溶解、混合与悬浮法,转换成另一种局部施药型式。 However, this solution may be added on formulation adjuvants other physiologically compatible, by known dissolving, mixing and suspension, into another type of topical application.

[0069] 本发明局部用产品较佳为呈溶液形式使用。 [0069] The present invention is preferably used as a topical product in the form of a solution. 根据本发明较佳局部用产品包含: According to the present invention, preferred topical products comprising:

[0070] 0.01至20重量% —种或多种活性成份, [0070] 0.01 to 20 wt.% - one or more active ingredients,

[0071] I至99.99重量%乳酸、苹果酸、酒石酸或柠檬酸的一种或多种C1-C4-烷基酯与 [0071] I to wt.% Of one lactic, malic, tartaric or citric 99.99 or more alkyl acrylate and C1-C4-

[0072] O至98.99重量% —种或多种生理上可相容的辅剂。 [0072] O to 98.99 wt.% - one or more physiologically compatible adjuvants.

[0073] 本发明亦有关以本发明局部用产品于治疗、预防、后处理或支持性治疗疣、指甲疾病与甲周疾病,及指甲保养上的应用。 [0073] The present invention is also related to the present invention is applied topical products for the treatment, prevention, after-treatment or supportive treatment of warts, nail diseases and periungual diseases, maintenance and nails. 此外,本发明尚有关以本发明产品于治疗家畜与宠物的蹄、爪与钩爪的霉菌感染上的应用。 In addition, the present invention is still related to the product of the invention in the treatment of livestock and pet hooves, claws application on fungal infections and of hooks.

[0074] 例如含抗霉菌剂的局部用产品适用于下列疾病: [0074] The antimycotic agent containing e.g. topical products suitable for the following diseases:

[0075]-治疗、预防与后处理由皮真菌、酵母菌或霉菌或混合感染所引起的甲真菌病, [0075] - the treatment, prevention and treatment of dermatophytes, yeasts, or molds, or mixed infection caused by onychomycosis,

[0076]-治疗、预防与后处理牛皮癣、糖尿病或AIDS患者的指甲霉菌感染, [0076] - treatment, prevention and treatment of psoriasis, diabetes or AIDS patients nail fungal infection,

[0077]-支持性治疗甲周的指甲感染,如,例如:假丝酵母(Candida paronychium)。 [0077] - nail infections a week of supportive care, such as, for example: Candida (Candida paronychium).

[0078] 例如含抗生素的局部用产品适用于例如下列疾病:[0079]-支持性治疗与/或预防细菌所引起的指甲-与甲周感染。 [0078] For example topical products containing antibiotics suitable, for example the following diseases: [0079] - the nail supportive treatment and / or prevention of a bacterial caused - and periungual infection.

[0080] 例如含抗菌剂的局部用产品适用于例如下列疾病: [0080] For example topical antibacterial agent containing product suitable, for example the following diseases:

[0081]-治疗与预防非特异性或未判别的病原菌所引起的指甲-与甲周感染。 [0081] - the treatment and prevention of non-specific pathogens or discrimination caused by nails - with a week of infection.

[0082] 例如含皮质类固醇或由皮质类固醇与抗霉菌剂、抗生素或抗菌剂组合成的局部用产品适用于例如下列疾病: [0082] such as those containing corticosteroids or combinations of corticosteroids and antimycotic agents, antibiotic or antibacterial agents into topical products suitable, for example the following diseases:

[0083]-治疗、预防、后处理或支持性治疗疣、指甲-皮癣或其它发炎的指甲-与甲周疾病。 [0083] - the treatment, prevention, after-treatment or supportive treatment of warts, nail - psoriasis or other inflammatory nails - and periungual diseases.

[0084] 本发明局部用医药产品适用于治疗疣、手指与脚指的指甲疾病与甲周疾病,并可治疗宠物与家畜的蹄、爪与钩爪的疾病。 [0084] The pharmaceutical products of the present invention suitable for topical treatment of warts, and finger and toe nails A disease periodontal disease, and treatment of hoof, claw finger diseases of livestock and pets. 医药产品的施药频率依疾病的程度与位置而定。 The frequency of administration of pharmaceutical products according to the degree and location of the disease may be. 通常一天施药I至3次即足够。 A typical day administration I to 3 times that is enough. 溶液可直接施用至指甲患处,或蹄、爪或钩爪,且若需要时,可施药至患处周围皮肤。 Solution may be applied directly to the affected nails or hooves, claws or hooks, and if necessary, administration to the affected area the surrounding skin. 该疗法应在症状消除后继续施药约2周,以防止复发。 The treatment should continue for about two weeks after administration elimination of symptoms, to prevent recurrence.

[0085] 根据本发明包含一种或多种滋养与合成代谢物质的局部用美容产品适用于保养指甲,如,例如:脚指与手指的指甲萎缩。 [0085] According to the present invention comprises one or more anabolic nourishing substances suitable for topical care and nail cosmetic product, such as, for example: the finger and toe nails atrophy. 指甲萎缩包括例如:脆、裂与薄指甲,及出现斑点或线条状白斑。 Nail atrophy include, for example: brittle, thin and split nails, and white spots or stripe-shaped. 该制剂是施用于不美观的指甲上,且可依需要施用在周围皮肤上。 The formulation is applied to the unsightly nails need to be administered also may depend on the surrounding skin. 制剂的施药频率依萎缩的程度与位置而异。 The frequency of administration of the formulation according to the degree of atrophy varies with position. 通常,一天施用1-2次即足够。 Typically, administered 1-2 times a day is sufficient.

[0086] 本发明局部用产品的优点在于其可使活性成分在几天内进入指甲患部,并在指甲床与指甲根处发挥作用。 [0086] advantages of the present invention, the topical product in that it allows the active ingredients into the affected area in the nail within a few days, and play a role in the nail bed and the nail root. 透过较快速开始的作用及其改善的渗透作用,可使指甲疾病的治疗通常在约2至3个月后结束。 Through its role in a more rapid onset of improvement in penetration, can treat nail disease usually ends in about 2-3 months later. 依此方式显然可改善患者的适应性,因为其大幅缩短其它方法所需的长时间治疗。 Obviously this manner can improve patient compliance, because it significantly reduces the treatment time required by other methods. 在皮肤患部,特别是甲周皮肤部位上,其痊愈过程及保养效果较快,因为活性成分可充分且快速渗入皮肤中。 In the affected area of ​​the skin, especially on the periphery of the skin site A, and its healing process faster maintenance effect, because the active ingredient can be fully and rapidly penetrate the skin. 指甲保养通常进行一个月。 Nail Care is usually carried out for a month. 若要维持健康指甲,亦可长期使用指甲保养产品。 To maintain healthy nails, nail care products can also be long-term use. 具体实施方式 Detailed ways

[0087] 下列实例是说明本发明: [0087] The following examples are illustrative of the invention:

[0088]实例 1: [0088] Example 1:

[0089] 克霉峻(Clotrimazol)-溶液I % [0089] g mycophenolate Jun (Clotrimazol) - I% solution

乳酸乙酯 20.0毫升 Ethyl lactate 20.0 ml

尿素 2.0克 2.0 g of urea

克霉峻(Clotrimazol) 1.0克 G mycophenolate Jun (Clotrimazol) 1.0 g

乳酸乙酯 加至I 00.0毫升 Ethyl lactate was added to I 00.0 mL

[0090] 搅拌添加尿素至20毫升乳酸乙酯中,于100毫升烧瓶中加热(约50°C )溶解。 [0090] Urea was added with stirring to 20 ml of ethyl lactate was heated (about 50 ° C) was dissolved in 100 ml flask. 搅拌添加克霉唑(Clotrimazol)至上述溶液中,然后添加乳酸乙酯至100毫升。 Clotrimazole was added with stirring (clotrimazol) to the above solution, and then ethyl lactate was added to 100 ml. 继续搅拌至形成均匀溶液为止。 Stirring was continued until a homogeneous solution is formed up.

[0091]实例 2: [0091] Example 2:

[0092] 金钟柏油 2.0% [0092] 2.0% thuja oil

[0093] 乳酸乙酯 98.0% [0093] Ethyl lactate 98.0%

[0094]实例 3:[0095] 金钟柏油 2.0% [0094] Example 3: [0095] 2.0% thuja oil

[0096] 茶树精油 1.0% [0096] Tea Tree Oil 1.0%

[0097]乳酸 2.0% [0097] 2.0% lactic acid

[0098] 乳酸乙酯 95.0% [0098] Ethyl lactate 95.0%

[0099]实例 4: [0099] Example 4:

[0100] 金钟柏油 2.0% [0100] 2.0% thuja oil

[0101]水杨酸 2.0% [0101] Salicylic acid 2.0%

[0102] 苹果酸乙酯96.0% [0102] malic acid ethyl ester 96.0%

[0103]实例 5: [0103] Example 5:

[0104] 环吡酮胺 8.0% [0104] ciclopirox 8.0%

[0105] (Ciclopiroxolamin) [0105] (Ciclopiroxolamin)

[0106] 乳酸乙酯 92.0% [0106] Ethyl lactate 92.0%

[0107]实例 6: [0107] Example 6:

[0108]乙醇 5.0%·[0109] ^^一碳烯酸10.0% [0108] Ethanol 5.0% - [0109] ^ ^ a carbon acid 10.0%

[0110] 柠檬酸甲酯85.0% [0110] Citric acid methyl ester 85.0%

[0111]实例 7: [0111] Example 7:

[0112] 熏衣草油 2.0% [0112] 2.0% lavender oil

[0113] ^^一碳烯酸10.0% [0113] ^^ a carbon acid 10.0%

[0114] 乳酸乙酯 88.0% [0114] Ethyl lactate 88.0%

[0115]实例 8: [0115] Example 8:

[0116] [0116]

克霉唆(Clotrimazol)-茶树精油-溶液I %+1 0% G mycophenolate instigate (clotrimazol) - tea tree oil - was I% + 1 0%

乳酸乙酯 20.0毫升 Ethyl lactate 20.0 ml

尿素 2.0克 2.0 g of urea

克霉唆(Clotrimazol) 1.0克 G mycophenolate instigate (Clotrimazol) 1.0 g

茶树精油 1.0克 1.0 g of tea tree oil

乳酸乙酯 加至100.0毫升 Ethyl lactate was added to 100.0 ml

[0117] 搅拌添加尿素至20毫升乳酸乙酯中,于100毫升烧瓶中加热(约50°C)溶解。 [0117] Urea was added with stirring to 20 ml of ethyl lactate was heated (about 50 ° C) was dissolved in 100 ml flask. 搅拌添加克霉唑(Clotrimazol)与茶树精油至上述溶液中,然后添加乳酸乙酯至100毫升。 Clotrimazole was added with stirring (clotrimazol) and tea tree oil to the solution, and then ethyl lactate was added to 100 ml. 继续搅拌至形成均匀溶液为止。 Stirring was continued until a homogeneous solution is formed up.

[0118]实例 9: [0118] Example 9:

[0119]茶树精油溶液30% 乳酸乙酯 44.0克茶树精油 30.0克熏衣草油 6.0克丙二醇 2U O克 [0119] 30% tea tree oil solution of 44.0 g ethyl lactate 30.0 g Tea Tree Oil of lavender oil 6.0 g Propylene glycol 2U O g

[0120] 量取所有物质加至烧杯中,搅拌至形成均匀溶液为止。 [0120] All substances added to a weighed beaker, stirred until a homogeneous solution is formed up.

[0121]实例 10: [0121] Example 10:

[0122] [0122]

ABC油-溶液2% 丙二醇 20.0克乳酸乙酯 72.0克茶树精油 1.0克熏衣草油 5.0克 ABC Oil - 2% solution of propylene glycol 20.0 g Ethyl lactate 72.0 g Tea Tree Oil 1.0 g lavender oil 5.0 g

[0123] 搅拌混合物至形成均匀溶液为止。 [0123] until the mixture was stirred until a homogeneous solution is formed.

[0124]实例 11: [0124] Example 11:

[0125] 脯氨酸-溶液1.5% [0125] proline - 1.5% solution

[0126] L-脯氨酸 1.5克 [0126] L- proline 1.5 g

[0127]丙二醇 65.0 克 [0127] Propylene glycol 65.0 g

[0128] 乳酸乙酯 33.5克 [0128] 33.5 g of ethyl lactate

[0129] 搅拌添加L-脯氨酸至丙二醇中,并加热溶解。 [0129] L- proline was added with stirring to propylene glycol, and dissolved by heating. 最后添加乳酸乙酯,继续搅拌至形成均匀溶液为止。 Finally, ethyl lactate was added, stirring is continued until a homogeneous solution is formed up.

[0130]实例 12: [0130] Example 12:

[0131] L-脯氨酸 2.0克 [0131] L- proline 2.0 g

[0132] 苹果酸二乙基酯93.0克 [0132] 93.0 g malic acid diethyl ester

[0133] 异丙醇 5.0克 [0133] 5.0 g of isopropanol

[0134] 搅拌添加L-脯氨酸至苹果酸二乙基酯中,继续搅拌至完全溶解为止。 [0134] L- proline was added to the stirred malic acid diethyl ester, the stirring was continued until completely dissolved.

[0135]实例 13: [0135] Example 13:

[0136] 下表中出示本发明组合物,其是使用各50.0克根据本发明的羟基羧酸-C1-C4-烷基酯作为载剂及各1.0克活性成分。 [0136] in the table show compositions of the invention, which is used as a carrier and each 50.0 g of active ingredient 1.0 g of each hydroxycarboxylic acid according to the present invention, -C1-C4- alkyl esters. 组合物的制法是于室温下或稍加温下(约30°C至500C )搅拌添加活性成分至羟基羧酸酯中。 Method composition at room temperature or at a temperature slightly (about 500C between 30 ° C) was added with stirring to the active ingredient hydroxy acid ester. 依活性成分而异,搅拌1-5小时后,形成立即可使用的溶液。 Varies depending on the active ingredient, after stirring for 1-5 hours, a solution can be used immediately.

[0137] [0137]

Figure CN103357015AD00161
Figure CN103357015AD00171

[0138]实例 14: [0138] Example 14:

[0139] 下表中出示本发明其它组合物,其是使用各88.0克根据本发明的羟基羧 [0139] The present invention is presented in the following table other compositions, each of which is the use of 88.0 g hydroxycarboxylic according to the present invention

酸-C1-C4-烷基酯作为载剂及由5克熏衣草油、5克荼树精油与2克印楝树提取物组成的 -C1-C4- alkyl ester acid as a carrier and 5 g of lavender oil, tea tree oil and 5 g 2 g neem tree extract composition

12.0克活性成分组合。 12.0 g of active ingredient combination. 组合物制法是于室温下搅拌添加活性成分至所使用的各羟基羧酸酯 The composition is prepared by stirring at room temperature was added each of the hydroxy carboxylic acid ester of the active ingredient to be used

中。 in. 所得的组合物即可使用。 The resulting compositions can be used.

[0140] [0140]

Figure CN103357015AD00172

Claims (19)

1.一种局部用产品在用于制造治疗疣的药物中的应用,其中所述局部用产品包含a) 一种或多种活性成份, b)作为载剂的一种或多种乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4-烷基酯,及C)可视需要选用的生理上可兼容的辅剂。 In the manufacture of a medicament for the treatment of warts application 1. A topical product, wherein said topical product comprising a) one or more active ingredients, b) as a carrier of one or more lactic acid, tartaric acid, citric acid, a i ^ i ^ alkanoic acid or a carbon acid esters of C1-C4- alkyl, and C) optionally physiologically compatible adjuvants selected.
2.如权利要求1所述的应用,其特征在于所述局部用产品包含的所述载剂选自乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的乙酯。 2. The use of claim 1, a carbon acid, characterized in that the carrier of the topical product selected from the group comprising lactic, malic, tartaric, citric, i ^ i ^ a of acid or ethyl ester.
3.如权利要求1所述的应用,其特征在于所述局部用产品包含的所述载剂选自乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的异丙基酯。 3. The use of claim 1, a carbon acid, characterized in that the carrier of the topical product selected from the group comprising lactic, malic, tartaric, citric, i ^ i ^ a of acid or isopropyl ester.
4.如权利要求1或2所述的应用,其特征在于所述局部用产品包含的所述载剂为乳酸乙酯。 Or the use as claimed in claim 12, wherein said carrier is a topical product comprises ethyl lactate.
5.如权利要求1至3中任一所述的应用,其特征在于所述局部用产品包含的所述载剂为十一烷酸甲酯或十一碳烯酸甲酯。 5. The use of any one of 1 to 3 according to claim, wherein the said carrier is a topical product containing methyl undecanoate or methyl undecylenate.
6.如权利要求1至3中任一所述的应用,其特征在于所述局部用产品包含的所述载剂为苹果酸二乙基酯。 Application of any one of 1 to 3 according to claim 6, wherein said carrier is a topical product containing malic acid diethyl ester.
7.如权利要求1中所述的应用。 7. Use according to claim 1. 其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的物质作为所述活性成分:合成或天然的抗霉菌剂、抗生素、抗菌剂、皮质类固醇及滋养与合成代谢物质。 Wherein said topical product comprising one or more selected from the group consisting of the following substances in each group was used as the active ingredient: synthetic or natural anti-fungal agents, antibiotics, antibacterial agents, corticosteroids and nourishes Synthesis metabolites.
8.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的所述抗霉菌活性成份:(±)-顺式_2,6- 二甲基-4- [2-甲基-3-(对-叔戍基-苯基)丙基]吗啉(安莫芬(Amorolfin))、两性霉素(Amphotericin)、6_环己基-1-轻基-4-甲基-2 (IH)-卩比唳酮(环匹罗司(Ciclopirox))、双-苯基-(2-氯苯基)-1-咪唑基甲烷(克霉唑(Clotrimazol))、1_[2_(2,4-二氯苯基)-2-(4-氯苯甲基氧)-乙基]-咪唑(益康唑(Econazol))、2,4-二氟-α,α-双(1Η-1,2,4_三唑-1-基甲基)苯甲基醇(氟康唑(Fluconazol))、5_氟胞卩密丨淀(安确治(Flucytosin))、7_氯-三甲氧基-甲基螺-[苯并呋喃-环己烯]-二酮(灰黄霉素(Griseofulvin))、1-[2,4-二氯-β-(2,6-二氯苯甲基氧)-苯乙基]-咪唑(异康唑(Isoconazol))、(±)-1-仲丁基-4-{4-[4-(4-{[ (2R*,4S*)-2-(2,4- 二氯苯基)-2-(1,2, 4-三唑-1-基甲基)-1,3- 二氧戊环-4-基]甲氧基}苯基)-1-哌嗪基 8. Application according to claim 1, wherein said topical product comprising one or more compounds selected from the group consisting of the following composition antimycotic active ingredients: (±) - cis _ 2,6-dimethyl-4- [2-methyl-3- (p - tert - pentyl - phenyl) propyl] morpholine (An Mofen (Amorolfin)), amphotericin (amphotericin), 6 _ light-cyclohexyl-1-yl-4-methyl -2 (IH) - one Jie Li ratio (ciclopirox (ciclopirox)), bis - phenyl - (2-chlorophenyl) -1-imidazolyl methane (clotrimazole (clotrimazol)), 1_ [2_ (2,4- dichlorophenyl) -2- (4-chlorobenzyl-oxy) - ethyl] - imidazole (econazole (Econazol)), 2,4-difluoro -α, α- bis (1Η-1,2,4_ triazol-1-ylmethyl) benzyl alcohol (fluconazole (Fluconazol)), 5_-fluoro-cell adhesion Shu Jie lake (Ann determined rule (Flucytosin)), 7_ chloro - trimethoxy - methyl - spiro - [benzofuran - cyclohexenyl] - dione (griseofulvin (griseofulvin)), 1- [2,4 - dichloro -β- (2,6- dichlorobenzyl oxy) - phenethyl] - imidazole (isoconazole (Isoconazol)), (±) -1- sec-butyl-4- {4- [ 4- (4 - {[(2R *, 4S *) - 2- (2,4- dichlorophenyl) -2- (1,2,4-triazol-1-ylmethyl) -1,3 - dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl ]苯基}-4,5-二氢-1,2,4-三唑-5-酮(伊曲康唑(Itraconazol) ),(±)顺式-1-乙酰基_4_{4-([2-(2,4-二氯苯基)-2-(1H-咪唑-1-基甲基)_1,3-二氧戍环-4-基]甲氧基)苯基}哌嗪(酮康唑(Ketoconazol))、1-[2,4-二氯-β - (2,4-二氯苯甲基氧)-苯乙基]-咪唑(咪康唑(Miconazol))、(E)-N-肉桂基-N-甲基-1-萘基甲基胺(萘替芬(Naftifin))、制霉菌素(Nystatin)、(E)-(6,6-二甲基-2-庚烯-4-炔基)-N-甲基-1-萘基甲基胺(特比萘芬(Terbinaf in))、1-[2-{(2-氯-3-噻吩基)甲氧基}-2-(2,4_ 二氯苯基)乙基]-1H-咪唑(噻康唑(Tioconazol))、0-2-萘基-N-甲基-N_(3-甲苯基)_硫代氨基甲酸酯(托萘酯(Tolnaftat))、α-(2,4_ 二氟苯基)-5_氟-β-甲基- α- (1Η_1,2,4-三唑-1-基甲基)-4_嘧啶乙醇(伏立康唑(Voriconazol))。 ] Phenyl} -4,5-dihydro-1,2,4-triazol-5-one (Itraconazole (Itraconazol)), (±) cis -1-acetyl-_4_ {4- ( [2- (2,4-dichlorophenyl) -2- (1H- imidazol-1-ylmethyl) _1,3- Shu-dioxo-4-yl] methoxy) phenyl} piperazine ( ketoconazole (Ketoconazol)), 1- [2,4- dichloro [beta] -D - (2,4-dichlorobenzyl oxy) - phenethyl] - imidazole (miconazole (Miconazol)), (E ) -N- -N- methyl-cinnamyl-1-naphthyl methylamine (naftifine (Naftifin)), nystatin (nystatin), (E) - (6,6- dimethyl-2- hept-en-4-yn-yl) -N- methyl-1-naphthylmethyl amine (terbinafine (Terbinaf in)), 1- [2 - {(2- chloro-3-thienyl) methoxy yl} -2- (2,4_-dichlorophenyl) ethyl] -1H- imidazole (tioconazole (Tioconazol)), 0-2- naphthyl -N- methyl -N_ (3- methylphenyl) _ thiocarbamate (tolnaftate (Tolnaftat)), α- (2,4_-difluorophenyl) -β- -5_ fluoro-methyl - α- (1Η_1,2,4- triazol-1 ylmethyl) pyrimidine -4_ ethanol (voriconazole (Voriconazol)).
9.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自:茶树精油、熏衣草油、金钟柏油、印楝树提取物和ABC油中的所述抗细菌或所述抗霉菌活性成分。 The tea tree oil, lavender oil, thuja oil, neem tree oil extract and ABC: The application as claimed in claim 1, wherein said topical product selected from the group comprising one or more the said anti-mycotic or antibacterial active ingredient.
10.如权利要求1中所述的应用,其特征在于所述局部用产品中包含一种或多种选自金钟柏油与ABC油中的所述抗细菌或所述抗霉菌活性成分。 10. Use according to claim 1, wherein said topical product selected from the group comprising one or more of the ABC thuja oil and oil of the anti-mycotic or antibacterial active ingredient.
11.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的所述抗生素活性成份:α -氨基-4-羟基苯甲基青霉素(羟氨苄青霉素(Amoxicillin))、D-(-)-a -氨基苯甲基青霉素(氨节青霉素(Ampicillin))、3,3- 二甲基-7-氧代-6-苯基乙酰胺基-4-硫杂-1-氮杂双环-[3.2.0]-庚烷-2-羧酸(苄青霉素)、苄青霉素-苄星、3-氯-7-D(2-苯基甘氨酸氨基)-头孢酸(头孢克洛(Cefaclor))、7β-0)-2-氨基-(4-羟基-苯基)-乙酰基氨基]_3_甲基-头孢酸(头孢羟氨(Cefadroxil))、氨基苯基-乙酰氨基-甲基-头孢酸(头孢氨苄(Cefalexin))、D (-)-对-2- 二氯乙酸氨基-1- (4-硝基苯基)-1, 3-丙二醇(氯霉素(Chloramphenicol)、1-环丙基-6-氣-1,4- 二氧~4~氧代-7-(1-喊嚷基)~3~喧琳竣酸(环丙沙星(Ciprofloxacin))、(Z) - (2R, 5R) -3- (2-羟基亚乙基)~7~ 氧代-4-氧杂-1-氮杂双环[3.2.0]庚烧-2-羧酸(克拉维酸(Clavulanic acid))、7_ 11. Use according to claim 1, wherein said topical product comprising one or more of the antibiotic active ingredient is selected from the group consisting of the following composition are in: α - amino-4-hydroxyphenyl methyl penicillins (amoxicillin (amoxicillin)), D - (-) - a - amino benzyl penicillin (ampicillin (ampicillin)), 3,3- dimethyl-7-oxo-6-phenyl yl acetamido-4-thia-1-azabicyclo - [3.2.0] - heptane-2-carboxylic acid (benzylpenicillin), benzylpenicillin - benzathine, 3-chloro -7-D (2- phenylglycine amino) - cephem acid (cefaclor (cefaclor)), 7β-0) -2- amino - (4-hydroxy - phenyl) - acetylamino] methyl _3_ - cephem acid (cefadroxil (Cefadroxil)), amino phenyl - acetamido - methyl - cephem acid (cephalexin (cefalexin)), D (-) - of acid-2-amino-1- (4-nitrophenyl) - 1, 1,3-propanediol (chloramphenicol (chloramphenicol), 1- cyclopropyl-6-dioxo-1,4 ~ gas ~ 4-oxo-7- (1-Hanrang yl) ~ 3 ~ noise Lin Jun acid (ciprofloxacin (ciprofloxacin)), (Z) - (2R, 5R) -3- (2- hydroxyethylidene) ~ ~ 7-oxo-4-oxa-1-azabicyclo [3.2. 0] hept-2-carboxylic acid burn (clavulanic acid (clavulanic acid)), 7_ 氯-7-脱氧-林可霉素(氯林可霉素(Clindamycin))、6_脱氧-5-轻基四环素(强力霉素(Doxycyclin))、1-乙基-6-氟-1,4- 二氢-4-氧代-7- (1-哌嗪基)-1, 8-萘啶_3_羧酸(依诺沙辛(Enoxacin))、红霉素、3-(2-氯-6-氟苯基)-5_甲基-4-异恶唑基-青霉素(氟氯西林(Flucloxacillin))、卡那霉素(Kanamycin)、林可霉素(Lincomycin)、7_二甲基氛基-6-脱氧-6-去甲基四环素(二甲胺四环素(Minocyc-lin))、6-(2_乙氧基-1-萘酰胺基)_青霉素(萘夫西林(Nafcilin))、1-乙基-1,4-二氢-7-甲基_4_氧代-1,8-萘啶-3-羧酸(萘唳酮酸(Nalidxic acid))、新霉素(Neomycin)、1-乙基_6_ 氟-1, 4_ 二氢~4~ 氧代-7- (1-哌嗪基)-3-喹啉羧酸(诺氟沙星(Norfloxacin))、(±) _9_氟-2,3- 二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de] [1,4]苯并恶嗪_6_羧酸(氧氟沙星(Ofloxacin) )、6_ (5-甲基_3_苯基-4-异恶唑羧酰胺基)青霉烷酸(甲苯异恶唑青霉素(Oxacillin) )、6 _苯氧基乙 Chloro-7-deoxy - lincomycin (clindamycin (Clindamycin)), 6_ light-deoxy-5-yl tetracycline (doxycycline (Doxycyclin)), 1- ethyl-6-fluoro-1, dihydro-4-oxo-7- (1-piperazinyl) -1, 8-naphthyridine _3_ acid (by Nuosha Xin (Enoxacin)), erythromycin, 3- (2- chloro-6-fluorophenyl) methyl-4-isoxazolyl -5_ - penicillin (flucloxacillin (flucloxacillin)), kanamycin (kanamycin), lincomycin (lincomycin), 7_ two methyl-6-deoxy atmosphere -6-demethyl-tetracycline (minocycline (Minocyc-lin)), 6- (2_ amido-ethoxy-1-naphthyl) _ penicillin (nafcillin (Nafcilin )), 1-ethyl-1,4-dihydro-7-methyl _4_ oxo-1,8-naphthyridine-3-carboxylic acid (Li-naphthalene acid (Nalidxic acid)), neomycin (Neomycin), ethyl 1- _6_ fluoro-l, 4 ~ 4_ ~ dihydro-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (norfloxacin (norfloxacin)), ( ±) _9_-fluoro-2,3-dihydro-3-methyl-10- (4-methylpiperazin-1-piperazinyl) -7-oxo -7H- pyrido [1,2,3-de ] [1,4] benzoxazine _6_ acid (ofloxacin (ofloxacin)), 6_ (5- methyl-_3_-phenyl-4-isoxazole carboxamide yl) penicillanate (toluene-isoxazolyl penicillin (Oxacillin)), 6 _ phenoxyacetate 基氨基-青霉烷酸(苯氧基甲基青霉素)与4-二甲基胺基-八氢-五羟基-1,11- 二氧代-6-甲基-萘并萘-2-脲(四环素)。 Group - penicillanate (phenoxymethyl penicillin) with 4-dimethylamino - octahydro - five-1,11-dioxo-6-methyl - urea naphthalene and naphthalene-2 (tetracycline).
12.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的所述抗菌活性成分:烷基苯甲基二甲基氯化铵(苯扎氯氨)、N-苯甲基-N,N-二甲基-2-{2-[对-(1,1,3, 3-四甲基丁基)-苯氧基]-乙氧基}-乙基氢氧化铵(氯化节乙氧铵)、鲸腊基三甲基氢氧化铵(西曲溴铵(Cetrimonium bromid))、I, I'-六亚甲基-双-[5_(对氯苯基)-双缩胍](洗必泰(Chlorhexidin))、N1, N1-十亚甲基-双_(4_氨基甲基喹哪唳鐵氢氧化物)(克菌定(Dequalinium chlorid))、N-(4_氯苯基)-N' _(3,4-二氯苯基)脲(三氯二苯脲(Triclocarbane))、5_ 氯-2-(2, 4-二氯苯氧基)苯酹(三氯生(Triclosan))。 Benzene dimethacrylate: 12. Use according to claim 1, wherein said topical product comprising one or more compounds selected from the group consisting of the following antibacterial composition active ingredient ammonium chloride (benzalkonium chloride, ammonia), N- benzyl -N, N- dimethyl-2- {2- [p - (1,1,3,3-tetramethylbutyl) - phenoxy yl] - ethoxy} - ethyl ammonium hydroxide (v benzethonium chloride), cetyl trimethyl ammonium hydroxide (cetrimide (cetrimonium bromid)), I, I'- hexamethylene yl - bis - [5_ (p-chlorophenyl) - biguanide] (chlorhexidine (Chlorhexidin)), N1, N1- decamethylene - _ bis (aminomethyl quinoline 4_ iron hydroxide which Li ) (dequalinium (dequalinium chlorid)), N- (4_ chlorophenyl) -N '_ (3,4- dichlorophenyl) urea (triclocarban (Triclocarbane)), 5_-chloro-2 - (2, 4-dichlorophenoxy) phenyl sprinkle (triclosan (triclosan)).
13.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的所述皮质类固醇活性成分:9α-氯-16β_甲基氢化波尼松(倍氯米松(Beclomethason))、9_ 氟-11 β,17,21-三轻基-16 β -甲基-1,4-孕二稀-3, 20- 二丽(倍他米松(Betamethason)) >21-氣-9-氣-11 β , 17- 二轻基-16 β -甲基-1,4-孕二烯-3,20- 二酮(氯倍米松(Clobetasol))、17,21- 二羟基-孕-4-烯-3,11,20-三酮(可的松(Cortisone))、11 β,16 α,17 α,21-四羟基_1,4-孕二烯-3,20-二酮-16,17-丙酮缩醛(丙缩羟强龙(Desonid) )、9_氟-11 β-17,21-三羟基-16 α -甲基孕留-1,4_ 二烯_3,20- 二酮(地塞米松(Dexamethason) )、9α,11β -二氯_6α -氟-21-羟基_16α,17α -(异亚丙基二氧)-孕甾-1,4- 二烯-3,20- 二酮(氟氯奈德(Flucloronid))、6 α,9 α - 二氟-16 α, 17 α -异亚丙基二氧-皮质酮(肤轻松(Fluocinolonacetonid) )、6α,9α -二氟-16 13. Use according to claim 1, wherein said topical product selected from the group comprising one or more of the corticosteroid active ingredient group consisting of the following composition: 9α- chloro -16β_ A prednisolone group (beclomethasone (Beclomethason)), 9_ fluoro -11 β, 17,21- three light-yl -16 β - methyl-1,4-diene-pregnant -3, 20-Li (x betamethasone (Betamethason))> 21- gas -9- gas -11 β, 17- two light-yl -16 β - methyl-1,4-pregnadiene-3,20-dione (chloro-fold dipropionate (Clobetasol )), 17,21-dihydroxy - -3,11,20- trione-4-ene (cortisone (cortisone)), 11 β, 16 α, 17 α, 21- tetrahydroxy _1,4 - pregnadiene-3,20-dione 16,17-acetal with acetone (prop-hydroxyethyl condensing prednisolone (Desonid)), 9_ fluoro -11 β-17,21- trihydroxy -16 α - methyl pregnancy _3,20- left -1,4_ diene dione (dexamethasone (dexamethason)), 9α, 11β - dichloro _6α - fluoro-21-hydroxy-_16α, 17α - (isopropylidene dioxy) - pregna-1,4-diene-3,20-dione (budesonide chlorofluorocarbons (Flucloronid)), 6 α, 9 α - difluoro -16 α, 17 α - isopropylidene-dioxo - cortex one (fluocinolone acetonide (Fluocinolonacetonid)), 6α, 9α - difluoro -16 α, 17 α -异亚丙基二氧-皮质酮-乙酸盐(醋酸氟轻松(Fluocinonid))、6 α -氟-11 β,21- 二轻基-6 α,17-异亚丙基二氧-4-孕烯-3,20- 二酮(氟氢缩松(Fludroxycortid))、3_(2_氯乙氧基)_9α -氟-6-甲酰基-11β,21- 二羟基-16α,17α -异亚丙基二氧孕-3,5- 二烯-20-酮(福莫可他(Formocortal)) >21-氯_9 α -氟-11 β -轻基-16 α,17 α -异亚丙基二氧-4-孕烯-3,20-二酮(哈西萘德(Halcinonid) )、17 α-羟基皮质酮(氢化可的松(Hydrocortison))、11 β,17, 21-三轻基-6 α -甲基-1, 4-孕二烯-3,20-二酮(甲基氢化泼尼松(Methylprednisolon))、11 β,17, 21-三轻基-孕-1, 4- 二烯-3, 20- 二酮(强的松龙(Prednisolon))、17 α,21- 二轻基-孕-1, 4- 二烯-3, 11, 20-三酮(泼尼松(Prednison))、9-氟-16α-羟基氢化泼尼松(丙酮氟羟泼尼松龙(Triamcinolon))、丙酮氟羟泼尼松龙-16 α,17 α -丙酮化物(曲安奈德(Triamcinolonacetonid))。 α, 17 α - isopropylidene-dioxo - Corticosterone - acetate (fluocinolone (Fluocinonid)), 6 α - fluoro -11 β, 21- two light-yl -6 α, 17- isopropylidene dioxo-4- pregnene-3,20-dione (flurandrenolide (Fludroxycortid)), 3_ (2_ chloroethoxy) _9α - fluoro-6-formyl -11β, 21- dihydroxy -16α , 17α - isopropylidene-dioxo-3,5-dien-20-one progestin (formocortal (formocortal))> 21- chloro _9 α - fluoro -11 β - light-yl -16 α, 17 α - isopropylidene-dioxo-4- pregnene-3,20-dione (naphthalene de hash (Halcinonid)), 17 α- hydroxy corticosterone (hydrocortisone (Hydrocortison)), 11 β, 17 , three light-yl 21 -6 α - methyl-1,4-pregnadiene-3,20-dione (methylprednisolone (Methylprednisolon)), 11 β, 17, 21- three light-yl - pregnancy-1,4-diene -3, 20-dione (prednisolone (Prednisolon)), 17 α, 21- two light-yl - pregnancy-1,4-diene -3, 11, 20 three one (prednisone (Prednison)), 9- fluoro-prednisolone-hydroxy -16α- (triamcinolone acetone (Triamcinolon)), triamcinolone acetone -16 α, 17 α - acetonide (triamcinolone acetonide (Triamcinolonacetonid)).
14.如权利要求1中所述的应用,其特征在于所述局部用产品包含滋养与合成代谢物质L-脯氨酸。 14. Use according to claim 1, wherein said topical product comprising nourishing and anabolic substances L- proline.
15.如权利要求1中所述的应用,其特征在于所述局部用产品包含所述L-脯氨酸与一种或多种选自氨基酸、维生素与矿物质所组成群中的滋养与合成代谢物质的组合。 15. Use according to claim 1, wherein said topical product containing L- proline with said selected one or more amino acids, the synthesis of trophoblast group consisting of vitamins and minerals metabolic combination of materials.
16.如权利要求1中所述的应用,其特征在于所述局部用产品包含所述L-脯氨酸与一种或多种选自:赖氨酸、半胱氨酸、明胶、生物素、泛酰醇、泛醇与无机或有机钙、镁或锌化合物的滋养与合成代谢物质的组合。 16. Use according to claim 1, wherein said topical product containing the L- proline with one or more selected from the group: lysine, cysteine, gelatin, biotin , panthenol, nourishing combination with panthenol anabolic substance with inorganic or organic calcium, magnesium or zinc compound.
17.如权利要求1中所述的应用,其特征在于所述局部用产品包含一种或多种选自下列各物所组成群中的辅剂:萜烯`或含萜烯的油、醇、酮、脂肪酸酯、聚乙二醇、表面活性剂、尿素、抗氧化剂与络合剂。 17. Use according to claim 1, wherein said topical product comprising one or more selected from the group consisting of the following composition adjuvants: `terpene or terpene-containing oils, alcohols , ketones, fatty acid esters, polyethylene glycol, a surfactant, urea, antioxidants and complexing agents.
18.如权利要求1中所述的应用,其特征在于所述局部用产品包含0.01至20重量%的一种或多种活性成份,I至99.99重量%的乳酸、苹果酸、酒石酸、柠檬酸、i^一烷酸或i^一碳烯酸的C1-C4-烷基酯,与O至98.99重量%辅剂。 18. Use according to claim 1, wherein said topical product containing 0.01 to 20 weight percent of one or more active ingredients, I-99.99% by weight of lactic acid, malic acid, tartaric acid, citric acid , i ^ i ^ an acid or a carbon acid esters of C1-C4- alkyl, with O to 98.99% by weight of adjuvants.
19.权利要求1所述的应用中的所述局部用产品在制造用于治疗宠物与家畜的蹄、爪与钩爪霉菌感染的药物中的应用。 Application of claim 1 in the manufacture hoof topical products for treating pets and livestock, with the pawl finger fungal infection 19. A medicament as claimed in claim.
CN2013102038263A 2005-09-29 2005-09-29 Local preparation for removing verruca and nail diseases and taking care of nails CN103357015A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2013102038263A CN103357015A (en) 2005-09-29 2005-09-29 Local preparation for removing verruca and nail diseases and taking care of nails
CN200510105663.02005.09.29 2005-09-29

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013102038263A CN103357015A (en) 2005-09-29 2005-09-29 Local preparation for removing verruca and nail diseases and taking care of nails

Publications (1)

Publication Number Publication Date
CN103357015A true CN103357015A (en) 2013-10-23

Family

ID=49359808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013102038263A CN103357015A (en) 2005-09-29 2005-09-29 Local preparation for removing verruca and nail diseases and taking care of nails

Country Status (1)

Country Link
CN (1) CN103357015A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509464A (en) * 2015-01-23 2018-04-05 バイオシディウム バイオファーマスーティカルズ インコーポレイテッド Antibacterial composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143793A (en) * 1991-03-08 2000-11-07 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6740326B1 (en) * 1998-09-10 2004-05-25 Bioequal Ag Topical nail care compositions
CN1631369A (en) * 2003-12-23 2005-06-29 高克 Cream for treating skin disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143793A (en) * 1991-03-08 2000-11-07 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6740326B1 (en) * 1998-09-10 2004-05-25 Bioequal Ag Topical nail care compositions
CN1631369A (en) * 2003-12-23 2005-06-29 高克 Cream for treating skin disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509464A (en) * 2015-01-23 2018-04-05 バイオシディウム バイオファーマスーティカルズ インコーポレイテッド Antibacterial composition

Similar Documents

Publication Publication Date Title
AU2005294216B2 (en) Organo-gel formulations for therapeutic applications
JP3081766B2 (en) Horny reservoir type antifungal composition for external use
ES2258347T3 (en) Topic anhydra preparations for skin that ketoconazol includes.
KR101301116B1 (en) Spreading implement
US20070196452A1 (en) Flux-enabling compositions and methods for dermal delivery of drugs
JP5756250B2 (en) Local vasoconstrictors and methods for protecting cells during cancer chemotherapy and radiation therapy
CN1195550C (en) External preparation
US20110245215A1 (en) Transdermal delivery systems for active agents
US20090069364A1 (en) Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
US20120065180A1 (en) Androgen pharmaceutical composition and method for treating depression
CA2646667C (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
AU2003270273B2 (en) Solution for ungual application
AU2006326388B2 (en) Compositions and methods for treating dermatological conditions
ES2240634T3 (en) Topical administration compositions with formation of deposit of external active principle, its preparation as well as its use.
JP2002512192A (en) Pharmaceutical compositions
JP2003535020A (en) Antifungal nail preparations for the treatment
CN1407898A (en) Novel topical oestroprogestational compositions with systemic effect
WO1999039680A1 (en) Antifungal nail lacquer and method using same
KR101662186B1 (en) Transdermal delivery system
JPH0892097A (en) Bifonazole-containing fungicidal composition
KR100530263B1 (en) Antimicotic nail varnish composition
CN1633280A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
JP2001505930A (en) Hormone replacement therapy agent for topical application to the skin
JP2562455B2 (en) Improved penetration topical pharmaceutical compositions
WO2005049025A1 (en) Method and composition for treatment of cutaneous lesions

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189488

Country of ref document: HK

C12 Rejection of a patent application after its publication